evrazkarЕвразийский Кардиологический ЖурналEurasian heart journal2225-16852305-0748Евразийская ассоциация кардиологов10.38109/2225-1685-2025-4-6-39evrazkar-6555Research ArticleКОНСЕНСУСCONSENSUSАмилоидоз сердца: консенсус Евразийской ассоциации кардиологов (ЕАК)Cardiac amyloidosis: consensus of the Eurasian Association of Cardiologists (EAC)https://orcid.org/0000-0002-4066-2661ЖировИ. В.ZhirovI. V.

Жиров Игорь Витальевич, д.м.н., ведущий научный сотрудник, отдел заболеваний миокарда и сердечной недостаточности

ул. Академика Чазова, дом 15а, г. Москва 121552

Igor V. Zhirov, Dr. of Scien. (Med.), Leading Researcher, Department of Myocardial Diseases and Heart Failure

Academician Chazov Street, Building 15a, Moscow 121552

izhirov@mail.ruhttps://orcid.org/0000-0002-0920-7417НасоноваС. Н.NasonovaS. N.

Насонова Светлана Николаевна, к.м.н., старший научный сотрудник, отдел заболеваний миокарда и сердечной недостаточности

г. Москва

ул. Академика Чазова, дом 15а, г. Москва 121552

Svetlana N. Nasonova, Cand. of Scien. (Med.), Senior Researcher, Department of Myocardial Diseases and Heart Failure

Moscow

dr.nasonova@mail.ruhttps://orcid.org/0000-0002-7817-3847МоисееваО. М.MoiseevaO. M.

Моисеева Ольга Михайловна, д.м.н., профессор, главный научный сотрудник, руководитель НИО некоронарогенных заболеваний сердца

г. Санкт-Петербург

Olga M. Moiseeva, Dr. of Scien. (Med.), Professor, Chief Researcher, Head of the Research Institute for Non-Coronary Heart Diseases

St. Petersburg

moiseeva@almazovcentre.ruhttps://orcid.org/0000-0001-5440-4340РехтинаИ. Г.RekhtinaI. G.

Рехтина Ирина Германовна, д.м.н., зав. отделением гематологии и химиотерапии плазмоклеточных дискразий

г. Москва

Irina G. Rekhtina, Dr. of Scien. (Med.), Head of the Department of Hematology and Chemotherapy of Plasma Cell Dyscrasias

Moscow

https://orcid.org/0000-0003-3956-6362СупоневаН. А.SuponevaN. A.

Супонева Наталья Александровна, д.м.н., член-корреспондент РАН, профессор РАН, директор, главный научный сотрудник, Института нейрореабилитации и восстановительных технологий

г. Москва

Natalia A. Suponeva, Dr. of Scien. (Med.), Corresponding Member of the Russian Academy of Sciences, Professor of the Russian Academy of Sciences, Director, Chief Researcher

Moscow

https://orcid.org/0000-0002-2675-3276АншелесА. А.AnshelesА. A.

Аншелес Алексей Аркадьевич, д.м.н., профессор, ведущий научный сотрудник, отдел радионуклидной диагностики и позитронно-эмиссионной томографии

г. Москва

Aleksey A. Ansheles, Dr. of Scien. (Med.), Professor, Leading Researcher, Department of Radionuclide Diagnostics and Positron Emission Tomography

 

https://orcid.org/0000-0002-4642-3610БарбарашО. Л.BarbarashO. L.

Барбараш Ольга Леонидовна, д.м.н., профессор, академик РАН, директор; заведующая кафедрой кардиологии

г. Кемерово

Olga L. Barbarash, Academician of RAS, Professor, Dr. of Sci. (Med.), Director of the Research Institute for Complex Issues of Cardiovascular Diseases; Head of the Cardiology Department

Kemerovo

olb61@mail.ruhttps://orcid.org/0000-0002-4510-6197ГалявичА. С.GalyavichA. S.

Галявич Альберт Сарварович, д.м.н., профессор заведующий кафедрой кардиологии ФПК и ППС

г. Казань

Albert S. Galyavich, Dr. of Sci. (Med.), Professor, Head of the Department of Cardiology, Faculty of Advanced Training and Professional Development

Kazan 

agalyavich@mail.ruhttps://orcid.org/0000-0002-6453-2976ДупляковД. В.DuplyakovD. V.

Дупляков Дмитрий Викторович, д.м.н., профессор, зам. главного врача по медицинской части; главный кардиолог Самарской области; заведующий кафедрой пропедевтической терапии с курсом кардиологии

г. Самара

Dmitry V. Duplyakov, Dr. of Sci. (Med.), Professor, Deputy Chief Physician for Medical Affairs; Chief Cardiologist of the Samara Region; Head of the Department of Propaedeutic Therapy with a Course in Cardiology

Samara

https://orcid.org/0000-0001-7065-2045ЗатейщиковД. А.ZateishchikovD. A.

Затейщиков Дмитрий Александрович, д.м.н. профессор, зав. кафедрой терапии, кардиологии и функциональной диагностики с курсом нефрологии; заведующий первичным сосудистым отделением

г. Москва

Dmitry A. Zateishchikov, Dr. of Sci. (Med.), Professor, Head of the Department of Therapy, Cardiology and Functional Diagnostics with a Course in Nephrology; Head of the Primary Vascular Department

Moscow

dz@bk.ruhttps://orcid.org/0000-0002-3233-1862СаидоваМ. А.SaidovaM. A.

Саидова Марина Абдулатиповна, д.м.н., профессор, руководитель отдела ультразвуковых методов исследования томографии

г. Москва

Marina A. Saidova, Dr. of Sci. (Med.), Professor, Head of the Department of Ultrasound Tomography Research Methods

Moscow

https://orcid.org/0000-0002-2251-1675ЧайковскаяО. Я.TchaikovskayaO. Ya.

Чайковская Ольга Ярославна, врач функциональной диагностики, отдел ультразвуковых методов исследования

г. Москва

Olga Ya. Tchaikovskaya, physician of functional diagnostics, Department of Ultrasound Research Methods

Moscow

https://orcid.org/0000-0002-0370-5204ШарияМ. А.ShariyaM. A.

Шария Мераб Арчилович, д.м.н., ведущий научный сотрудник отдела томографии; профессор кафедры лучевой диагностики

г. Москва

 

Merab A. Shariya, Dr. of Sci. (Med.), Leading Researcher, Tomography Department, E.I. Chazov National Medical Research Center of Cardiology; Professor, Department of Radiation Diagnostics

Moscow

mershar@yandex.ruhttps://orcid.org/0000-0001-9234-6129ТерещенкоС. Н.TereshchenkoS. N.

Терещенко Сергей Николаевич, д.м.н., профессор, руководитель отдела заболеваний миокарда и сердечной недостаточности

г. Москва

Sergey N. Tereshchenko, Dr. of Sci. (Med.), Professor, Head of the Department of Myocardial Diseases and Heart Failure

Moscow

stereschenko@yandex.ruФГБУ «НМИЦ кардиологии им. академика Е.И.Чазова» Минздрава РоссииРоссияE.I. Chazov National Medical Research Center of CardiologyRussian FederationФГБУ «НМИЦ имени В.А. Алмазова»РоссияAlmazov National Medical Research CenterRussian FederationФГБУ «НМИЦ гематологии» Минздрава РоссииРоссияNational Medical Research Center of HematologyRussian FederationФГБУ «Российский центр неврологии и нейронаук»РоссияInstitute of Neurorehabilitation and Restorative Technologies, Russian Center for Neurology and NeurosciencesRussian FederationФГБУ «НМИЦ кардиологии им. академика Е.И.Чазова» Минздрава РоссииРоссияFederal State Budgetary Institution "NMITsK named after Academician E.I. Chazov" of the Ministry of Health of the Russian FederationRussian FederationФГБНУ «НИИ КПССЗ»; ФГБОУ ВО КГМА Минздрава РоссииРоссияKemerovo State Medical AcademyRussian FederationФГБОУ ВО «Казанский ГМУ» Минздрава РоссииРоссияKazan State Medical UniversityRussian FederationГБУЗ «Самарский областной клинический кардиологический диспансер им. В.П. Полякова; ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава РоссииРоссияV.P. Polyakov Samara Regional Clinical Cardiology Dispensary; Samara State Medical UniversityRussian FederationФГБУ ДПО «Центральная государственная медицинская академия» УД Президента РФ; ГБУЗ «ГКБ №29 им. Н.Э. Баумана ДЗМ»РоссияCentral State Medical Academy; N.E. Bauman City Clinical Hospital No. 29Russian FederationФГБУ «НМИЦ кардиологии им. академика Е.И.Чазова» Минздрава России; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian FederationФГБУ «НМИЦ кардиологии им. академика Е.И.Чазова» Минздрава РоссииРоссияE.I. Chazov National Medical Research Center of Cardiology of the Ministry of Health of the Russian FederationRussian Federation20252611202504639Copyright © Жиров И.В., Насонова С.Н., Моисеева О.М., Рехтина И.Г., Супонева Н.А., Аншелес А.А., Барбараш О.Л., Галявич А.С., Дупляков Д.В., Затейщиков Д.А., Саидова М.А., Чайковская О.Я., Шария М.А., Терещенко С.Н., 20252025Жиров И.В., Насонова С.Н., Моисеева О.М., Рехтина И.Г., Супонева Н.А., Аншелес А.А., Барбараш О.Л., Галявич А.С., Дупляков Д.В., Затейщиков Д.А., Саидова М.А., Чайковская О.Я., Шария М.А., Терещенко С.Н.Zhirov I.V., Nasonova S.N., Moiseeva O.M., Rekhtina I.G., Suponeva N.A., Ansheles А.A., Barbarash O.L., Galyavich A.S., Duplyakov D.V., Zateishchikov D.A., Saidova M.A., Tchaikovskaya O.Y., Shariya M.A., Tereshchenko S.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.heartj.asia/jour/article/view/6555

Амилоидоз является системным заболеванием, поражающим не только сердечно-сосудистую систему. В документе наиболее широко обсуждается этиология, патогенез, особенности клинического течения двух типов амилоидоза AL- и ATTR. Суммированы данные обновленных международных протоколов и рекомендаций по диагностике амилоидоза. Представлен краткий обзор по методам инвазивной и неинвазивной диагностики и их сочетаниям, для каждой из диагностических опций и инструментов приводится анализ доказательной базы. В статье описан адаптированный алгоритм последовательной диагностики и дифференциальной диагностики пациентов с подозрением на АКМП с учетом сочетания клинических проявлений и данных обследования. В статье освящена проблема как специфического лечения AL- и ATTR, так и симптоматической терапии, как сердечной недостаточности, нарушений ритма и проводимости, так и неврологических проявлений. Документ будет полезен как врачам первичного звена, так и узким специалистам: кардиологам, неврологам, гематологам и нефрологам.

Amyloidosis is a systemic disease affecting not only the cardiovascular system. The paper discusses etiology, pathogenicity, features of clinical course of two types of amyloidosis AL- and ATTR. Data from updated international protocols and recommendations for the diagnosis of amyloidosis are summarized. A brief overview of invasive and non-invasive diagnostic methods and their combinations is provided, with an analysis of the evidence base for each of the diagnostic options and tools. The article describes an adapted algorithm for sequential diagnosis and differential diagnosis of patients with suspicion of ACM, taking into account the combination of clinical manifestations and examination data. The article covers the problem of specific treatment of AL- and ATTR, as well as symptomatic therapy, both heart failure, rhythm and conduction disorders, and neurological manifestations. The document will be useful both for primary level doctors and narrow specialists: cardiologists, neurologists, hematologists and nephrologists.

амилоидная кардиомиопатиятранстиретиновая полинейропатияAL-амилоидозATTR-амилоидозклинические рекомендациидиагностикаспецифическая терапияamyloid cardiomyopathytransthyretin polyneuropathyAL-amyloidosisATTR-amyloidosisclinical recommendationsdiagnosisspecific therapyReferencesBuxbaum JN, Dispenzieri A, Eisenberg DS, Fändrich M, Merlini G, Saraiva MJM, Sekijima Y, Westermark P. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2022 Dec;29(4):213-219. https://doi.org/10.1080/13506129.2022.2147636Buxbaum JN, Dispenzieri A, Eisenberg DS, Fändrich M, Merlini G, Saraiva MJM, Sekijima Y, Westermark P. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2022 Dec;29(4):213-219. https://doi.org/10.1080/13506129.2022.2147636Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017 Apr 4;135(14):13571377. https://doi.org/10.1161/CIRCULATIONAHA.116.024438Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017 Apr 4;135(14):13571377. https://doi.org/10.1161/CIRCULATIONAHA.116.024438Madan N, Kalra D. Clinical evaluation of infiltrative cardiomyopathies resulting in heart failure with preserved ejection fraction. Rev Cardiovasc Med. 2020 Jun 30;21(2):181-190, https://doi.org/10.31083/j.rcm.2020.02.65Madan N, Kalra D. Clinical evaluation of infiltrative cardiomyopathies resulting in heart failure with preserved ejection fraction. Rev Cardiovasc Med. 2020 Jun 30;21(2):181-190, https://doi.org/10.31083/j.rcm.2020.02.65Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. Adv Ther. 2015 Oct;32(10):920-8. https:// doi.org/10.1007/s12325-015-0250-0Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. Adv Ther. 2015 Oct;32(10):920-8. https:// doi.org/10.1007/s12325-015-0250-0Papoutsidakis N, Miller EJ, Rodonski A, Jacoby D. Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis. J Card Fail. 2018 Feb;24(2):131-133. https://doi.org/10.1016/j.cardfail.2017.12.005Papoutsidakis N, Miller EJ, Rodonski A, Jacoby D. Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis. J Card Fail. 2018 Feb;24(2):131-133. https://doi.org/10.1016/j.cardfail.2017.12.005Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641–54. https://doi.org/10.1016/S0140-6736(15)01274-XWechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641–54. https://doi.org/10.1016/S0140-6736(15)01274-XObi CA, Mostertz WC, Griffin JM, Judge DP. ATTR Epidemiology, Genetics, and Prognostic Factors. Methodist Debakey Cardiovasc J. 2022 Mar 14;18(2):17-26. https://doi.org/10.14797/mdcvj.1066Obi CA, Mostertz WC, Griffin JM, Judge DP. ATTR Epidemiology, Genetics, and Prognostic Factors. Methodist Debakey Cardiovasc J. 2022 Mar 14;18(2):17-26. https://doi.org/10.14797/mdcvj.1066Poli L, Labella B, Cotti Piccinelli S, Caria F, Risi B, Damioli S, Padovani A, Filosto M. Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy. Front Neurol. 2023 Oct 5;14:1242815. https://doi.org/10.3389/fneur.2023.1242815Poli L, Labella B, Cotti Piccinelli S, Caria F, Risi B, Damioli S, Padovani A, Filosto M. Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy. Front Neurol. 2023 Oct 5;14:1242815. https://doi.org/10.3389/fneur.2023.1242815Bart NK, Thomas L, Korczyk D, Atherton JJ, Stewart GJ, Fatkin D. Amyloid Cardiomyopathy. Heart Lung Circ. 2020 Apr;29(4):575-583. https://doi.org/10.1016/j.hlc.2019.11.019Bart NK, Thomas L, Korczyk D, Atherton JJ, Stewart GJ, Fatkin D. Amyloid Cardiomyopathy. Heart Lung Circ. 2020 Apr;29(4):575-583. https://doi.org/10.1016/j.hlc.2019.11.019, Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, Gospodinova M, Obici L, Rapezzi C, Garcia-Pavia P. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail. 2019 Aug;7(8):709-716. https://doi.org/10.1016/j.jchf.2019.04.010, Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, Gospodinova M, Obici L, Rapezzi C, Garcia-Pavia P. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail. 2019 Aug;7(8):709-716. https://doi.org/10.1016/j.jchf.2019.04.010Bukhari S. Cardiac amyloidosis: state-of-the-art review. J Geriatr Cardiol. 2023 May 28;20(5):361-375. https://doi.org/10.26599/1671-5411.2023.05.006Bukhari S. Cardiac amyloidosis: state-of-the-art review. J Geriatr Cardiol. 2023 May 28;20(5):361-375. https://doi.org/10.26599/1671-5411.2023.05.006Porcari A, Razvi Y, Masi A, Patel R, Ioannou A, Rauf MU, Hutt DF, Rowczenio D, Gilbertson J, Martinez-Naharro A, Venneri L, Whelan C, Lachmann H, Wechalekar A, Quarta CC, Merlo M, Sinagra G, Hawkins PN, Fontana M, Gillmore JD. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2023 Apr;25(4):515-524. https://doi.org/10.1002/ejhf.2776Porcari A, Razvi Y, Masi A, Patel R, Ioannou A, Rauf MU, Hutt DF, Rowczenio D, Gilbertson J, Martinez-Naharro A, Venneri L, Whelan C, Lachmann H, Wechalekar A, Quarta CC, Merlo M, Sinagra G, Hawkins PN, Fontana M, Gillmore JD. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2023 Apr;25(4):515-524. https://doi.org/10.1002/ejhf.2776Aung N, Nicholls HL, Chahal CAA, Khanji MY, Rauseo E, Chadalavada S, Petersen SE, Munroe PB, Elliott PM, Lopes LR. Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population. JAMA Cardiol. 2024 Nov 1;9(11):964-972. https://doi.org/10.1001/jamacardio.2024.2190Aung N, Nicholls HL, Chahal CAA, Khanji MY, Rauseo E, Chadalavada S, Petersen SE, Munroe PB, Elliott PM, Lopes LR. Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population. JAMA Cardiol. 2024 Nov 1;9(11):964-972. https://doi.org/10.1001/jamacardio.2024.2190Chandrashekar P, Alhuneafat L, Mannello M, Al-Rashdan L, Kim MM, Dungu J, Alexander K, Masri A. Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic Review. Circ Genom Precis Med. 2021 Oct;14(5):e003356. https://doi.org/10.1161/CIRCGEN.121.003356Chandrashekar P, Alhuneafat L, Mannello M, Al-Rashdan L, Kim MM, Dungu J, Alexander K, Masri A. Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic Review. Circ Genom Precis Med. 2021 Oct;14(5):e003356. https://doi.org/10.1161/CIRCGEN.121.003356Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, Grogan M, Kristen AV, Lousada I, Nativi-Nicolau J, Cristina Quarta C, Rapezzi C, Ruberg FL, Witteles R, Merlini G. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circ Heart Fail. 2019 Sep;12(9):e006075. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006075Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, Grogan M, Kristen AV, Lousada I, Nativi-Nicolau J, Cristina Quarta C, Rapezzi C, Ruberg FL, Witteles R, Merlini G. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circ Heart Fail. 2019 Sep;12(9):e006075. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006075Никитин С.С., Бардаков С.Н., Супонева Н.А. и др. Фенотипическая гетерогенность и особенности диагностики транстиретинового амилоидоза с полинейропатией. Нервно-мышечные болезни 2021;11(3):12–36. https://doi.org/10.17650/2222-8721-2021-11-3-12-36Nikitin S.S., Bardakov S.N., Suponeva N.A., Zhirov I.V., Adyan T.A., Grishina D.A., Deev R.V. Phenotypic heterogeneity and diagnostic features of transthyretin amyloidosis with polyneuropathy. Neuromuscular Diseases. 2021;11(3):12-36. (In Russ.) https://doi.org/10.17650/2222-8721-2021-11-3-12-36]Zaida L Almeida et al. Transthyretin mutagenesis: impact on amyloidogenesis and disease. Crit Rev Clin Lab Sci. 2024 Nov;61(7):616-640, https://doi.org/10.1080/10408363.2024.2350379Zaida L Almeida et al. Transthyretin mutagenesis: impact on amyloidogenesis and disease. Crit Rev Clin Lab Sci. 2024 Nov;61(7):616-640, https://doi.org/10.1080/10408363.2024.2350379Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellie C, Plante-Bordeneuve V (2008) Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 15:181–186. https://doi.org/10.1080/13506120802193720Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellie C, Plante-Bordeneuve V (2008) Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 15:181–186. https://doi.org/10.1080/13506120802193720WHO classification of Tumours. Haematolymphoid tumours. Tissues. 5-th Edition. 2024. P.930.WHO classification of Tumours. Haematolymphoid tumours. Tissues. 5-th Edition. 2024. P.930.Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and Survival Trends in Amyloidosis, 1987-2019. N Engl J Med. 2020, 16; 382(16):1567-1568. https://doi.org/10.1056/nejmc1917321Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and Survival Trends in Amyloidosis, 1987-2019. N Engl J Med. 2020, 16; 382(16):1567-1568. https://doi.org/10.1056/nejmc1917321Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016. 25; 387(10038):2641-2654. https://doi.org/10.1016/s0140-6736(15)01274-xWechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016. 25; 387(10038):2641-2654. https://doi.org/10.1016/s0140-6736(15)01274-xKumar N, Zhang NJ, Cherepanov D, Romanus D, Hughes M, Faller DV. Global epidemiology of amyloid light-chain amyloidosis. Orphanet J Rare Dis. 2022. 19; 17(1):278. https://doi.org/10.1186/s13023-022-02414-6Kumar N, Zhang NJ, Cherepanov D, Romanus D, Hughes M, Faller DV. Global epidemiology of amyloid light-chain amyloidosis. Orphanet J Rare Dis. 2022. 19; 17(1):278. https://doi.org/10.1186/s13023-022-02414-6Baker KR. Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication. Methodist Debakey Cardiovasc J. 2022. 14; 18(2):27-35. https://doi.org/10.14797/mdcvj.1070Baker KR. Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication. Methodist Debakey Cardiovasc J. 2022. 14; 18(2):27-35. https://doi.org/10.14797/mdcvj.1070Palladini G, Schönland S, Merlini G, Milani P, Jaccard A, Bridoux F, Dimopoulos MA, Ravichandran S, Hegenbart U, Roeloffzen W, Cibeira MT, Agis H, Minnema MC, Bergantim R, Hájek R, João C, Leonidakis A, Cheliotis G, Sonneveld P, Kastritis E, Wechalekar A. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J. 2023 Jan 25;13(1):19. https://doi.org/10.1038/s41408-023-00789-8Palladini G, Schönland S, Merlini G, Milani P, Jaccard A, Bridoux F, Dimopoulos MA, Ravichandran S, Hegenbart U, Roeloffzen W, Cibeira MT, Agis H, Minnema MC, Bergantim R, Hájek R, João C, Leonidakis A, Cheliotis G, Sonneveld P, Kastritis E, Wechalekar A. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J. 2023 Jan 25;13(1):19. https://doi.org/10.1038/s41408-023-00789-8Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, Lachmann HJ, Quarta C, Fontana M, Gillmore JD, Whelan C, Hawkins PN, Wechalekar AD. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019. 19;134(25):2271-2280. https://doi.org/10.1182/blood.2019000834Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, Lachmann HJ, Quarta C, Fontana M, Gillmore JD, Whelan C, Hawkins PN, Wechalekar AD. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019. 19;134(25):2271-2280. https://doi.org/10.1182/blood.2019000834Хышова В. А., Рехтина И. Г., Фирсова М. В., Менделеева Л. П. Трудности в диагностике первичного AL-амилоидоза. Онкогематология 2021;16(3):74-82. https://doi.org/10.17650/1818-8346-2021-16-3-74-82Khyshova V.A., Rekhtina I.G., Firsova M.V., Mendeleeva L.P. Difficulties in diagnosis of primary AL-amyloidosis. Oncohematology. 2021;16(3):74-82. (In Russ.) https://doi.org/10.17650/1818-8346-2021-16-3-74-82]Escher F, Senoner M, Doerler J, et al. When and how do patients with cardiac amyloidosis die? Clin Res Cardiol. 2020;109:78-88. https://doi.org/10.1007/s00392-019-01490-2Escher F, Senoner M, Doerler J, et al. When and how do patients with cardiac amyloidosis die? Clin Res Cardiol. 2020;109:78-88. https://doi.org/10.1007/s00392-019-01490-2Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. Adv Ther. 2015. 32(10):920-8. https://doi.org/10.1007/s12325-015-0250-0Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. Adv Ther. 2015. 32(10):920-8. https://doi.org/10.1007/s12325-015-0250-0Hipp MS, Park SH, Hartl FU. Proteostasis impairment in proteinmisfolding and -aggregation diseases. Trends Cell Biol 2014; 24:506-514. https://doi.org/10.1016/j.tcb.2014.05.003Hipp MS, Park SH, Hartl FU. Proteostasis impairment in proteinmisfolding and -aggregation diseases. Trends Cell Biol 2014; 24:506-514. https://doi.org/10.1016/j.tcb.2014.05.003Muchtar E, Dispenzieri A, Leung N, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia. 2018; 32(10):2240-2249. https://doi.org/10.1038/s41375-018-0060-xMuchtar E, Dispenzieri A, Leung N, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia. 2018; 32(10):2240-2249. https://doi.org/10.1038/s41375-018-0060-xShi J, Guan J, Jiang B et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a noncanonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A 2010; 107(9):4188-4193. https://doi.org/10.1073/pnas.0912263107Shi J, Guan J, Jiang B et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a noncanonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A 2010; 107(9):4188-4193. https://doi.org/10.1073/pnas.0912263107Mishra S, Guan J, Plovie E et al. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol 2013; 305(1):H95-103. https://doi.org/10.1152/ajpheart.00186.2013Mishra S, Guan J, Plovie E et al. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol 2013; 305(1):H95-103. https://doi.org/10.1152/ajpheart.00186.2013Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Hear Fail. 2019;7(8):709-716. https://doi.org/10.1016/j.jchf.2019.04.010Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Hear Fail. 2019;7(8):709-716. https://doi.org/10.1016/j.jchf.2019.04.010Yilmaz A, Bauersachs J, Bengel F, Büchel R, Kindermann I, Klingel K, et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021;110(4):479–506. Available from: https://doi.org/10.1007/s00392-020-01799-3Yilmaz A, Bauersachs J, Bengel F, Büchel R, Kindermann I, Klingel K, et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021;110(4):479–506. Available from: https://doi.org/10.1007/s00392-020-01799-3Younis M, Ogbu I, Kalra DK. Optimizing drug therapies in cardiac amyloidosis. Pharmacol Ther. 2025 Jan;265:108758. https://doi.org/10.1016/j.pharmthera.2024Younis M, Ogbu I, Kalra DK. Optimizing drug therapies in cardiac amyloidosis. Pharmacol Ther. 2025 Jan;265:108758. https://doi.org/10.1016/j.pharmthera.2024Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2023 Feb 3;118(18):3517-3535. https://doi.org/10.1093/cvr/cvac119Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2023 Feb 3;118(18):3517-3535. https://doi.org/10.1093/cvr/cvac119Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, Biagini E, Salvi F, Branzi A. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010 Jul;7(7):398-408. https://doi.org/10.1038/nrcardio.2010.67Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, Biagini E, Salvi F, Branzi A. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010 Jul;7(7):398-408. https://doi.org/10.1038/nrcardio.2010.67Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018 Oct 25;4(1):38. https://doi.org/10.1038/s41572-018-0034-3Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018 Oct 25;4(1):38. https://doi.org/10.1038/s41572-018-0034-3Чайковская О.Я., Саидова М.А., Добровольская С.В., Шошина А.А., Насонова С.Н., Жиров И.В., Терещенко С.Н. Эхокардиографические особенности фенотипов амилоидной кардиомиопатии у пациентов с различными типами амилоидоза. Терапевтический архив. 2025;97(4):315-321. https://doi.org/10.26442/00403660.2025.04.203168Сhaikovskaya OY, Saidova MA, Dobrovolskaya SV, Shoshina AA, Nasonova SN, Zhirov IV, Tereshchenko SN. Echocardiographic features of amyloid cardiomyopathy phenotypes in patients with different types of amyloidosis. Terapevticheskii arkhiv 2025;97(4):315-321. (In Russ.) https://doi.org/10.26442/00403660.2025.04.203168]Brito D, Albrecht FC, De Arenaza DP, Bart N, Better N, CarvajalJuarez I et al. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart 2023;18(1):59. https://doi.org/10.5334/gh.1262Brito D, Albrecht FC, De Arenaza DP, Bart N, Better N, CarvajalJuarez I et al. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart 2023;18(1):59. https://doi.org/10.5334/gh.1262Jaiswal V, Agrawal V, Khulbe Y, Hanif M, Huang H, Hameed M et al.Cardiac amyloidosis and aortic stenosis: a state-of-the-art review. European Heart Journal Open. 2023;3(6):oead106. https://doi.org/10.1093/ehjopen/oead106Jaiswal V, Agrawal V, Khulbe Y, Hanif M, Huang H, Hameed M et al.Cardiac amyloidosis and aortic stenosis: a state-of-the-art review. European Heart Journal Open. 2023;3(6):oead106. https://doi.org/10.1093/ehjopen/oead106Ahammed MR, Ananya FN. Cardiac Amyloidosis: A Comprehensive Review of Pathophysiology, Diagnostic Approach, Applications of Artificial Intelligence, and Management Strategies. Cureus. 2024 Jul 2;16(7):e63673. https://doi.org/10.7759/cureus.63673Ahammed MR, Ananya FN. Cardiac Amyloidosis: A Comprehensive Review of Pathophysiology, Diagnostic Approach, Applications of Artificial Intelligence, and Management Strategies. Cureus. 2024 Jul 2;16(7):e63673. https://doi.org/10.7759/cureus.63673Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, Mirelis JG, Baksi AJ, Moon JC, Garcia-Pavia P, Gillmore JD, Hawkins PN, Fontana M. High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis. J Am Coll Cardiol. 2019 Apr 9;73(13):1733-1734. https://doi.org/10.1016/j.jacc.2019.01.035Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, Mirelis JG, Baksi AJ, Moon JC, Garcia-Pavia P, Gillmore JD, Hawkins PN, Fontana M. High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis. J Am Coll Cardiol. 2019 Apr 9;73(13):1733-1734. https://doi.org/10.1016/j.jacc.2019.01.035Napolitano A, De Michieli L, Sinigiani G, Berno T, Cipriani A, Spiezia L. Thromboembolic and Bleeding Events in Transthyretin Amyloidosis and Coagulation System Abnormalities: A Review. J Clin Med. 2023 Oct 20;12(20):6640, https://doi.org/10.3390/jcm12206640Napolitano A, De Michieli L, Sinigiani G, Berno T, Cipriani A, Spiezia L. Thromboembolic and Bleeding Events in Transthyretin Amyloidosis and Coagulation System Abnormalities: A Review. J Clin Med. 2023 Oct 20;12(20):6640, https://doi.org/10.3390/jcm12206640Fotiou D, Theodorakakou F, Spiliopoulou S, Gavriatopoulou M, Migkou M, Kanellias N, Eleutherakis-Papaiakovou E, Malandrakis P, Dialoupi I, Roussou M, Ntanasis-Stathopoulos I, Terpos E, Dimopoulos MA, Kastritis E. Thrombotic and bleeding complications in patients with AL amyloidosis. Br J Haematol. 2024 May;204(5):1816-1824. https://doi.org/10.1111/bjh.19331Fotiou D, Theodorakakou F, Spiliopoulou S, Gavriatopoulou M, Migkou M, Kanellias N, Eleutherakis-Papaiakovou E, Malandrakis P, Dialoupi I, Roussou M, Ntanasis-Stathopoulos I, Terpos E, Dimopoulos MA, Kastritis E. Thrombotic and bleeding complications in patients with AL amyloidosis. Br J Haematol. 2024 May;204(5):1816-1824. https://doi.org/10.1111/bjh.19331Chacko L, Kotecha T, Ioannou A, Patel N, Martinez-Naharro A, Razvi Y, Patel R, Massa P, Venneri L, Brown J, Porcari A, Knott K, Manisty C, Knight D, Lockie T, Rakhit R, Lachmann H, Wechelakar A, Whelan C, Ponticos M, Moon J, González A, Gilbertson J, Riefolo M, Leone O, Xue H, Hawkins P, Kellman P, Gillmore J, Fontana M. Myocardial perfusion in cardiac amyloidosis. Eur J Heart Fail. 2024 Mar;26(3):598-609. https://doi.org/10.1002/ejhf.3137Chacko L, Kotecha T, Ioannou A, Patel N, Martinez-Naharro A, Razvi Y, Patel R, Massa P, Venneri L, Brown J, Porcari A, Knott K, Manisty C, Knight D, Lockie T, Rakhit R, Lachmann H, Wechelakar A, Whelan C, Ponticos M, Moon J, González A, Gilbertson J, Riefolo M, Leone O, Xue H, Hawkins P, Kellman P, Gillmore J, Fontana M. Myocardial perfusion in cardiac amyloidosis. Eur J Heart Fail. 2024 Mar;26(3):598-609. https://doi.org/10.1002/ejhf.3137Itzhaki Ben Zadok O, Vaxman I, Hoss S, Talmor-Barkan Y, Steinmetz T, Raanani P, Kornowski R, Hamdan A. Coronary Artery Disease and Microvascular Ischemia in Patients with Cardiac Amyloidosis. Acta Haematol. 2025;148(4):452-461. https://doi.org/10.1159/000542510Itzhaki Ben Zadok O, Vaxman I, Hoss S, Talmor-Barkan Y, Steinmetz T, Raanani P, Kornowski R, Hamdan A. Coronary Artery Disease and Microvascular Ischemia in Patients with Cardiac Amyloidosis. Acta Haematol. 2025;148(4):452-461. https://doi.org/10.1159/000542510Bashir Z, Younus A, Dhillon S, Kasi A, Bukhari S. Epidemiology, diagnosis, and management of cardiac amyloidosis. J Investig Med. 2024 Oct;72(7):620-632. https://doi.org/10.1177/10815589241261279Bashir Z, Younus A, Dhillon S, Kasi A, Bukhari S. Epidemiology, diagnosis, and management of cardiac amyloidosis. J Investig Med. 2024 Oct;72(7):620-632. https://doi.org/10.1177/10815589241261279Adams D, Ando Y, Beirão JM, Coelho T, Gertz MA, Gillmore JD, Hawkins PN, Lousada I, Suhr OB, Merlini G. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2021; 268(6):2109-2122. PMID: 31907599; PMCID: PMC8179912. https://doi.org/10.1007/s00415-019-09688-0Adams D, Ando Y, Beirão JM, Coelho T, Gertz MA, Gillmore JD, Hawkins PN, Lousada I, Suhr OB, Merlini G. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2021; 268(6):2109-2122. PMID: 31907599; PMCID: PMC8179912. https://doi.org/10.1007/s00415-019-09688-0Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, Said G, Salvi F. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013 Feb 20;8:31. PMID: 23425518; PMCID: PMC:3584981. https://doi.org/10.1186/1750-1172-8-31Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, Said G, Salvi F. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013 Feb 20;8:31. PMID: 23425518; PMCID: PMC:3584981. https://doi.org/10.1186/1750-1172-8-31Никитин С.С., Бардаков С.Н., Супонева Н.А. и др. Фенотипическая гетерогенность и особенности диагностики транстиретинового амилоидоза с полинейропатией. Нервно-мышечные болезни 2021;11(3):12-36. https://doi.org/10.17650/2222-8721-2021-11-3-12-36Никитин С.С., Бардаков С.Н., Супонева Н.А. и др. Фенотипическая гетерогенность и особенности диагностики транстиретинового амилоидоза с полинейропатией. Нервно-мышечные болезни 2021;11(3):12-36. https://doi.org/10.17650/2222-8721-2021-11-3-12-36Лысенко (Козловская) Л.В., Рамеев В.В., Моисеев С.В. и др. Клинические рекомендации по диагностике и лечению системного амилоидоза. Клин фармакол тер 2020;29(1):13-24. https://doi.org/10.32756/0869-5490-2020-1-13-24Lysenko (Kozlovskaya) LV, Rameev VV, Moiseev S, et al. Clinical guidelines for diagnosis and treatment of systemic amyloidosis. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Therapy 2020;29(1):13-24 (In Russ.) https://doi.org/10.32756/0869-5490-2020-1-13-24]Зиновьева О.Е., Сафиулина Э.И. Транстиретиновая амилоидная полинейропатия: патогенез, клинические особенности, перспективы лечения. Manage pain. 2017;4:12-5.Zinov'eva O.E., Safiulina E.I. Transtiretinovaia amiloidnaia polineiropatiia: patogenez, klinicheskie osobennosti, perspektivy lecheniia. Manage pain. 2017;4:12-5. [in Russ.]Адян Т.А., Поляков А.В. Наследственный транстиретиновый амилоидоз. Нервно-мышечные болезни. 2019;9(4):12-25. https://doi.org/10.17650/2222-8721-2019-9-4-12-25Адян Т.А., Поляков А.В. Наследственный транстиретиновый амилоидоз. Нервно-мышечные болезни. 2019;9(4):12-25. https://doi.org/10.17650/2222-8721-2019-9-4-12-25Mariani LL, Lozeron P, Theaudin M et al (2015) Genotypephenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 78:901-916. https://doi.org/10.1002/ana.24519Mariani LL, Lozeron P, Theaudin M et al (2015) Genotypephenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 78:901-916. https://doi.org/10.1002/ana.24519Coelho T, Vinik A, Vinik EJ, Tripp T, Packman J, Grogan DR (2017) Clinical measures in transthyretin familial amyloid polyneuropathy. Muscle Nerve 55:323-332. https://doi.org/10.1002/mus.25257Coelho T, Vinik A, Vinik EJ, Tripp T, Packman J, Grogan DR (2017) Clinical measures in transthyretin familial amyloid polyneuropathy. Muscle Nerve 55:323-332. https://doi.org/10.1002/mus.25257Milandri A, Farioli A, Gagliardi C, Longhi S, Salvi F, Curti S, Foffi S, Caponetti AG, Lorenzini M, Ferlini A, Rimessi P, Mattioli S, Violante FS, Rapezzi C. Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. Eur J Heart Fail. 2020 Mar;22(3):507-515. https://doi.org/10.1002/ejhf.1742Milandri A, Farioli A, Gagliardi C, Longhi S, Salvi F, Curti S, Foffi S, Caponetti AG, Lorenzini M, Ferlini A, Rimessi P, Mattioli S, Violante FS, Rapezzi C. Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. Eur J Heart Fail. 2020 Mar;22(3):507-515. https://doi.org/10.1002/ejhf.1742Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, Shapiro D, Evans PJ, Maschke S, Kilpatrick SE, Tan CD, Rodriguez ER, Monteiro C, Tang WHW, Kelly JW, Seitz WH Jr, Hanna M. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol. 2018 Oct 23;72(17):2040-2050, https://doi.org/10.1016/j.jacc.2018.07.092Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, Shapiro D, Evans PJ, Maschke S, Kilpatrick SE, Tan CD, Rodriguez ER, Monteiro C, Tang WHW, Kelly JW, Seitz WH Jr, Hanna M. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol. 2018 Oct 23;72(17):2040-2050, https://doi.org/10.1016/j.jacc.2018.07.092Westin O, Fosbøl EL, Maurer MS, Leicht BP, Hasbak P, Mylin AK, Rørvig S, Lindkær TH, Johannesen HH, Gustafsson F. Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome. J Am Coll Cardiol. 2022 Sep 6;80(10):967-977. https://doi.org/10.1016/j.jacc.2022.06.026Westin O, Fosbøl EL, Maurer MS, Leicht BP, Hasbak P, Mylin AK, Rørvig S, Lindkær TH, Johannesen HH, Gustafsson F. Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome. J Am Coll Cardiol. 2022 Sep 6;80(10):967-977. https://doi.org/10.1016/j.jacc.2022.06.026, Maurer MS, Smiley D, Simsolo E, Remotti F, Bustamante A, Teruya S, Helmke S, Einstein AJ, Lehman R, Giles JT, Kelly JW, Tsai F, Blaner WS, Brun PJ, Riesenburger RI, Kryzanski J, Varga C, Patel AR. Analysis of lumbar spine stenosis specimens for identification of amyloid. J Am Geriatr Soc. 2022 Dec;70(12):3538-3548. https://doi.org/10.1111/jgs.17976, Maurer MS, Smiley D, Simsolo E, Remotti F, Bustamante A, Teruya S, Helmke S, Einstein AJ, Lehman R, Giles JT, Kelly JW, Tsai F, Blaner WS, Brun PJ, Riesenburger RI, Kryzanski J, Varga C, Patel AR. Analysis of lumbar spine stenosis specimens for identification of amyloid. J Am Geriatr Soc. 2022 Dec;70(12):3538-3548. https://doi.org/10.1111/jgs.17976Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH. Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis. JAMA. 2017 Sep 12;318(10):962-963. https://doi.org/10.1001/jama.2017.9236Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH. Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis. JAMA. 2017 Sep 12;318(10):962-963. https://doi.org/10.1001/jama.2017.9236Rubin J, Alvarez J, Teruya S, Castano A, Lehman RA, Weidenbaum M, Geller JA, Helmke S, Maurer MS. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? Amyloid. 2017 Dec;24(4):226-230, https://doi.org/10.1080/13506129.2017.1375908Rubin J, Alvarez J, Teruya S, Castano A, Lehman RA, Weidenbaum M, Geller JA, Helmke S, Maurer MS. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? Amyloid. 2017 Dec;24(4):226-230, https://doi.org/10.1080/13506129.2017.1375908Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018 Oct 25;4(1):38. https://doi.org/10.1038/s41572-018-0034-3Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018 Oct 25;4(1):38. https://doi.org/10.1038/s41572-018-0034-3Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016 Jun 25;387(10038):2641-2654. https://doi.org/10.1016/S0140-6736(15)01274-XWechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016 Jun 25;387(10038):2641-2654. https://doi.org/10.1016/S0140-6736(15)01274-XStoopler ET, Alawi F, Laudenbach JM, Sollecito TP. Bullous amyloidosis of the oral cavity: a rare clinical presentation and review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Jun;101(6):734-40. https://doi.org/10.1016/j.tripleo.2006.01.003Stoopler ET, Alawi F, Laudenbach JM, Sollecito TP. Bullous amyloidosis of the oral cavity: a rare clinical presentation and review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Jun;101(6):734-40. https://doi.org/10.1016/j.tripleo.2006.01.003Рехтина И.Г., Хышова В.А., Зозуля Н.И., Двирнык В.Н., Менделеева Л.П. Нарушения гемостаза у пациентов с системным AL-амилоидозом. Терапевтический архив. 2023;95(9):746-750. https://doi.org/10.26442/00403660,2023.09.202372Рехтина И.Г., Хышова В.А., Зозуля Н.И., Двирнык В.Н., Менделеева Л.П. Нарушения гемостаза у пациентов с системным AL-амилоидозом. Терапевтический архив. 2023;95(9):746-750. https://doi.org/10.26442/00403660,2023.09.202372Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol. 2006 Dec;17(12):3458-71. https://doi.org/10.1681/ASN.2006050460Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol. 2006 Dec;17(12):3458-71. https://doi.org/10.1681/ASN.2006050460Sharma A, Bansal S, Jain R. Unique morphology of intratubular light chain casts in multiple myeloma: the amyloid cast nephropathy. Indian J Pathol Microbiol. 2014 Oct-Dec;57(4):629-31. https://doi.org/10.4103/0377-4929.142712Sharma A, Bansal S, Jain R. Unique morphology of intratubular light chain casts in multiple myeloma: the amyloid cast nephropathy. Indian J Pathol Microbiol. 2014 Oct-Dec;57(4):629-31. https://doi.org/10.4103/0377-4929.142712Gertz MA, Comenzo R, Falk RH et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005; 79(4):319-328. https://doi.org/10.1002/ajh.20381Gertz MA, Comenzo R, Falk RH et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005; 79(4):319-328. https://doi.org/10.1002/ajh.20381Насонова С.Н., Жиров И.В., Шошина А.А., Осмоловская Ю.Ф., Аншелес А.А., Чайковская О.Я., Добровольская С.В., Сергиенко В.Б., Саидова М.А., Терещенко С.Н., Бойцов С.А. Экспертный центр по амилоидозу сердца: реалии и перспективы. Терапевтический архив 2024;96(4):321-329. https://doi.org/10.26442/00403660.2024.04.202677Nasonova SN, Zhirov IV, Shoshina AA, Osmolovskaya YF, Ansheles AA, Tchaikovskaya OY, Dobrovolskaya SV, Sergienko VB, Saidova MA, Tereshchenko SN, Boytsov SA. Expert Center for cardiac amyloidosis: reality and perspectives. Terapevticheskii arkhiv 2024;96(4):321-329. (In Russ.) https://doi.org/10.26442/00403660.2024.04.202677]Takashio S, Yamamuro M, Izumiya Y, Hirakawa K, Marume K, Yamamoto M, Ueda M, Yamashita T, Ishibashi-Ueda H, Yasuda S, Ogawa H, Ando Y, Anzai T, Tsujita K. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail. 2018 Feb;5(1):27-35. https://doi.org/10.1002/ehf2.12203Takashio S, Yamamuro M, Izumiya Y, Hirakawa K, Marume K, Yamamoto M, Ueda M, Yamashita T, Ishibashi-Ueda H, Yasuda S, Ogawa H, Ando Y, Anzai T, Tsujita K. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail. 2018 Feb;5(1):27-35. https://doi.org/10.1002/ehf2.12203Zhang Y, Chaolu H. Diagnostic Role of NT-proBNP in Patients with Cardiac Amyloidosis Involvement: A Meta-Analysis. Arq Bras Cardiol. 2022 Aug;119(2):212-222. English, Portuguese. https://doi.org/10.36660/abc.20210486Zhang Y, Chaolu H. Diagnostic Role of NT-proBNP in Patients with Cardiac Amyloidosis Involvement: A Meta-Analysis. Arq Bras Cardiol. 2022 Aug;119(2):212-222. English, Portuguese. https://doi.org/10.36660/abc.20210486Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016 Sep 6;68(10):1014-20. https://doi.org/10.1016/j.jacc.2016.06.033Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016 Sep 6;68(10):1014-20. https://doi.org/10.1016/j.jacc.2016.06.033Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018 Aug 7;39(30):2799-2806. https://doi.org/10.1093/eurheartj/ehx589Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018 Aug 7;39(30):2799-2806. https://doi.org/10.1093/eurheartj/ehx589Adams D., Suhr O.B., Hund E. et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol 2016;29(1):S14–26. PMID: 26734952. https://doi.org/10.1097/wco.0000000000000289Adams D., Suhr O.B., Hund E. et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol 2016;29(1):S14–26. PMID: 26734952. https://doi.org/10.1097/wco.0000000000000289Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004 Sep 15;22(18):3751-7. https://doi.org/10.1200/JCO.2004.03.029Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004 Sep 15;22(18):3751-7. https://doi.org/10.1200/JCO.2004.03.029Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012 Mar 20;30(9):989-95. https://doi.org/10.1200/JCO.2011.38.5724Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012 Mar 20;30(9):989-95. https://doi.org/10.1200/JCO.2011.38.5724Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA, De Winter T, Elliott PM, Flather M, Garcia-Pavia P, Haugaa KH, Ingles J, Jurcut RO, Klaassen S, Limongelli G, Loeys B, Mogensen J, Olivotto I, Pantazis A, Sharma S, Van Tintelen JP, Ware JS, Kaski JP; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct 1;44(37):3503-3626. PMID: 37622657. https://doi.org/10.1093/eurheartj/ehad194Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA, De Winter T, Elliott PM, Flather M, Garcia-Pavia P, Haugaa KH, Ingles J, Jurcut RO, Klaassen S, Limongelli G, Loeys B, Mogensen J, Olivotto I, Pantazis A, Sharma S, Van Tintelen JP, Ware JS, Kaski JP; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct 1;44(37):3503-3626. PMID: 37622657. https://doi.org/10.1093/eurheartj/ehad194Cipriani A, De Michieli L, Porcari A, Licchelli L, Sinigiani G, Tini G, Zampieri M, Sessarego E, Argirò A, Fumagalli C, De Gaspari M, Licordari R, Russo D, Di Bella G, Perfetto F, Autore C, Musumeci B, Canepa M, Merlo M, Sinagra G, Gregori D, Iliceto S, Perazzolo Marra M, Cappelli F, Rapezzi C. Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value. JACC CardioOncol. 2022 Sep 7;4(4):458-470, https://doi.org/10.1016/j.jaccao.2022.08.007Cipriani A, De Michieli L, Porcari A, Licchelli L, Sinigiani G, Tini G, Zampieri M, Sessarego E, Argirò A, Fumagalli C, De Gaspari M, Licordari R, Russo D, Di Bella G, Perfetto F, Autore C, Musumeci B, Canepa M, Merlo M, Sinagra G, Gregori D, Iliceto S, Perazzolo Marra M, Cappelli F, Rapezzi C. Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value. JACC CardioOncol. 2022 Sep 7;4(4):458-470, https://doi.org/10.1016/j.jaccao.2022.08.007Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol. 2014 Oct 1;114(7):108993. https://doi.org/10.1016/j.amjcard.2014.07.026Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol. 2014 Oct 1;114(7):108993. https://doi.org/10.1016/j.amjcard.2014.07.026Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005 Feb 15;95(4):535-7. https://doi.org/10.1016/j.amjcard.2004.10.028Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005 Feb 15;95(4):535-7. https://doi.org/10.1016/j.amjcard.2004.10.028Cuddy SAM, Chetrit M, Jankowski M, Desai M, Falk RH, Weiner RB, Klein AL, Phelan D, Grogan M. Practical Points for Echocardiography in Cardiac Amyloidosis. J Am SocEchocardiogr. 2022 Sep;35(9):A31-A40. PMID: 36064258. https://doi.org/10.1016/j.echo.2022.06.006Cuddy SAM, Chetrit M, Jankowski M, Desai M, Falk RH, Weiner RB, Klein AL, Phelan D, Grogan M. Practical Points for Echocardiography in Cardiac Amyloidosis. J Am SocEchocardiogr. 2022 Sep;35(9):A31-A40. PMID: 36064258. https://doi.org/10.1016/j.echo.2022.06.006Elena Arbelo, Alexandros Protonotarios, Juan R Gimeno, Eloisa Arbustini, Roberto Barriales-Villa, Cristina Basso, Connie R Bezzina, Elena Biagini, Nico A Blom, Rudolf A de Boer, Tim De Winter, Perry M Elliott, Marcus Flather, Pablo Garcia-Pavia, Kristina H Haugaa, Jodie Ingles, RuxandraOanaJurcut, Sabine Klaassen, Giuseppe Limongelli, Bart Loeys, Jens Mogensen, IacopoOlivotto, AntonisPantazis, Sanjay Sharma, J Peter Van Tintelen, James S Ware, Juan Pablo Kaski, ESC Scientific Document Group, 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC), European Heart Journal, Volume 44, Issue 37, 1 October 2023, Pages 3503-3626. https://doi.org/10.1093/eurheartj/ehad194Elena Arbelo, Alexandros Protonotarios, Juan R Gimeno, Eloisa Arbustini, Roberto Barriales-Villa, Cristina Basso, Connie R Bezzina, Elena Biagini, Nico A Blom, Rudolf A de Boer, Tim De Winter, Perry M Elliott, Marcus Flather, Pablo Garcia-Pavia, Kristina H Haugaa, Jodie Ingles, RuxandraOanaJurcut, Sabine Klaassen, Giuseppe Limongelli, Bart Loeys, Jens Mogensen, IacopoOlivotto, AntonisPantazis, Sanjay Sharma, J Peter Van Tintelen, James S Ware, Juan Pablo Kaski, ESC Scientific Document Group, 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC), European Heart Journal, Volume 44, Issue 37, 1 October 2023, Pages 3503-3626. https://doi.org/10.1093/eurheartj/ehad194Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kühl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008 Jan;29(2):270-6. https://doi.org/10.1093/eurheartj/ehm342Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kühl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008 Jan;29(2):270-6. https://doi.org/10.1093/eurheartj/ehm342Благова О.В. и др. Болезни миокарда и перикарда: от синдромов к диагнозу и лечению/ [идр.]. — М.: ГЭОТАР-Медиа, 2019:753-771. ISBN: 978-5-9704-4743-7 [Blagova O.V. et al. Diseases of the myocardium and pericardium: from syndromes to diagnosis and treatment. — M.:GEOTAR-Media, 2019:753-771 (In Russ.) ISBN: 978-5-9704-4743-7]Благова О.В. и др. Болезни миокарда и перикарда: от синдромов к диагнозу и лечению/ [идр.]. — М.: ГЭОТАР-Медиа, 2019:753-771. ISBN: 978-5-9704-4743-7 [Blagova O.V. et al. Diseases of the myocardium and pericardium: from syndromes to diagnosis and treatment. — M.:GEOTAR-Media, 2019:753-771 (In Russ.) ISBN: 978-5-9704-4743-7]Rapezzi C, Aimo A, Barison A, Emdin M, Porcari A, Linhart A, Keren A, Merlo M, Sinagra G. Restrictive cardiomyopathy: definition and diagnosis. EurHeartJ. 2022 Dec 1;43(45):4679-4693. https://doi.org/10.1093/eurheartj/ehac543Rapezzi C, Aimo A, Barison A, Emdin M, Porcari A, Linhart A, Keren A, Merlo M, Sinagra G. Restrictive cardiomyopathy: definition and diagnosis. EurHeartJ. 2022 Dec 1;43(45):4679-4693. https://doi.org/10.1093/eurheartj/ehac543Writing Committee; Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, Dember LM, Frantz JG, Hershberger RE, Maurer MS, Nativi-Nicolau J, Sanchorawala V, Sheikh FH. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023 Mar 21;81(11):1076-1126. https://doi.org/10.1016/j.jacc.2022.11.022. Epub 2023 Jan 23. Erratum in: J Am Coll Cardiol. 2023 Mar 21;81(11):1135. https://doi.org/10.1016/j.jacc.2023.02.013Writing Committee; Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, Dember LM, Frantz JG, Hershberger RE, Maurer MS, Nativi-Nicolau J, Sanchorawala V, Sheikh FH. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023 Mar 21;81(11):1076-1126. https://doi.org/10.1016/j.jacc.2022.11.022. Epub 2023 Jan 23. Erratum in: J Am Coll Cardiol. 2023 Mar 21;81(11):1135. https://doi.org/10.1016/j.jacc.2023.02.013Dorbala, S., et al. (2021). "ASNC/AHA/ASE/EANM/HFSA/ISA/ SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2— Evidence Base and Standardized Methods of Imaging." Circulation: Cardiovascular Imaging 14(7):e000029. https://doi.org/10.1161/hci.0000000000000029Dorbala, S., et al. (2021). "ASNC/AHA/ASE/EANM/HFSA/ISA/ SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2— Evidence Base and Standardized Methods of Imaging." Circulation: Cardiovascular Imaging 14(7):e000029. https://doi.org/10.1161/hci.0000000000000029Damy T, Maurer MS, Rapezzi C, Planté-Bordeneuve V, Karayal ON, Mundayat R, Suhr OB, Kristen AV. Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart. 2016 Feb 8;3(1):e000289. PMID: 26870387; PMCID: PMC4746524. https://doi.org/10.1136/openhrt-2015-000289Damy T, Maurer MS, Rapezzi C, Planté-Bordeneuve V, Karayal ON, Mundayat R, Suhr OB, Kristen AV. Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart. 2016 Feb 8;3(1):e000289. PMID: 26870387; PMCID: PMC4746524. https://doi.org/10.1136/openhrt-2015-000289Rahman JE, Helou EF, Gelzer-Bell R, Thompson RE, Kuo C, Rodriguez ER, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am CollCardiol. 2004;43:410-5. https://doi.org/10.1016/j.jacc.2003.08.043Rahman JE, Helou EF, Gelzer-Bell R, Thompson RE, Kuo C, Rodriguez ER, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am CollCardiol. 2004;43:410-5. https://doi.org/10.1016/j.jacc.2003.08.043Phelan D, Collier P, Thavendiranathan P, Popović ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012;98:1442-8. https://doi.org/10.1136/heartjnl-2012-302353Phelan D, Collier P, Thavendiranathan P, Popović ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012;98:1442-8. https://doi.org/10.1136/heartjnl-2012-302353Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am SocEchocardiogr. 2015 Jan;28(1):1-39.e14. PMID: 25559473. https://doi.org/10.1016/j.echo.2014.10.003Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am SocEchocardiogr. 2015 Jan;28(1):1-39.e14. PMID: 25559473. https://doi.org/10.1016/j.echo.2014.10.003Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, Horton K, Ogunyankin KO, Palma RA, Velazquez EJ. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J Am SocEchocardiogr. 2019 Jan;32(1):1-64. Epub 2018 Oct 1. PMID: 30282592. https://doi.org/10.1016/j.echo.2018.06.004Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, Horton K, Ogunyankin KO, Palma RA, Velazquez EJ. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J Am SocEchocardiogr. 2019 Jan;32(1):1-64. Epub 2018 Oct 1. PMID: 30282592. https://doi.org/10.1016/j.echo.2018.06.004Pagourelias ED, Mirea O, Duchenne J, Van Cleemput J, Delforge M, Bogaert J, Kuznetsova T, Voigt JU. Echo Parameters for Differential Diagnosis in Cardiac Amyloidosis: A Head-to-Head Comparison of Deformation and Nondeformation Parameters. CircCardiovasc Imaging. 2017 Mar;10(3):e005588. PMID: 28298286. https://doi.org/10.1161/CIRCIMAGING.116.005588Pagourelias ED, Mirea O, Duchenne J, Van Cleemput J, Delforge M, Bogaert J, Kuznetsova T, Voigt JU. Echo Parameters for Differential Diagnosis in Cardiac Amyloidosis: A Head-to-Head Comparison of Deformation and Nondeformation Parameters. CircCardiovasc Imaging. 2017 Mar;10(3):e005588. PMID: 28298286. https://doi.org/10.1161/CIRCIMAGING.116.005588Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021 Apr;23 (4):512-526. Epub 2021 Apr 7. PMID: 33826207. https://doi.org/10.1002/ejhf.2140Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021 Apr;23 (4):512-526. Epub 2021 Apr 7. PMID: 33826207. https://doi.org/10.1002/ejhf.2140Yilmaz, A., Bauersachs, J., Bengel, F. et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021 Apr;110(4):479-506. https://doi.org/10.1007/s00392-020-01799-3Yilmaz, A., Bauersachs, J., Bengel, F. et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021 Apr;110(4):479-506. https://doi.org/10.1007/s00392-020-01799-3Rosa Lillo, Maurizio Pieroni, Antonia Camporeale, Michele Ciabatti, Antonella Lombardo, Massimo Massetti, Francesca Graziani. Echocardiography in Anderson-Fabry Disease. Rev. Cardiovasc. Med. 2022 May 31;23(6):201. https://doi.org/10.31083/j.rcm2306201Rosa Lillo, Maurizio Pieroni, Antonia Camporeale, Michele Ciabatti, Antonella Lombardo, Massimo Massetti, Francesca Graziani. Echocardiography in Anderson-Fabry Disease. Rev. Cardiovasc. Med. 2022 May 31;23(6):201. https://doi.org/10.31083/j.rcm2306201Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, Wollenweber T, Ahmed N, Thornton GD, Kelion AD, Sabharwal N, Newton JD, Ozkor M, Kennon S, Mullen M, Lloyd G, Fontana M, Hawkins PN, Pugliese F, Menezes LJ, Moon JC, Mascherbauer J, Treibel TA. Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis. J Am CollCardiol. 2021 Jan 19;77(2):128-139. Epub 2020 Nov 9. PMID: 33181246; PMCID: PMC7805267. https://doi.org/10.1016/j.jacc.2020,11.006Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, Wollenweber T, Ahmed N, Thornton GD, Kelion AD, Sabharwal N, Newton JD, Ozkor M, Kennon S, Mullen M, Lloyd G, Fontana M, Hawkins PN, Pugliese F, Menezes LJ, Moon JC, Mascherbauer J, Treibel TA. Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis. J Am CollCardiol. 2021 Jan 19;77(2):128-139. Epub 2020 Nov 9. PMID: 33181246; PMCID: PMC7805267. https://doi.org/10.1016/j.jacc.2020,11.006Aimo A, Camerini L, Fabiani I, Morfino P, Panichella G, Barison A, Pucci A, Castiglione V, Vergaro G, Sinagra G, Emdin M. Valvular heart disease in patients with cardiac amyloidosis. Heart Fail Rev. 2024 Jan;29(1):65-77. https://doi.org/10.1007/s10741-023-10350-1Aimo A, Camerini L, Fabiani I, Morfino P, Panichella G, Barison A, Pucci A, Castiglione V, Vergaro G, Sinagra G, Emdin M. Valvular heart disease in patients with cardiac amyloidosis. Heart Fail Rev. 2024 Jan;29(1):65-77. https://doi.org/10.1007/s10741-023-10350-1Okafor, J.; Khattar, R.; Sharma, R.; Kouranos, V. The Role of Echocardiography in the Contemporary Diagnosis and Prognosis of Cardiac Sarcoidosis: A Comprehensive Review. Life 2023;13:1653. https://doi.org/10.3390/life13081653Okafor, J.; Khattar, R.; Sharma, R.; Kouranos, V. The Role of Echocardiography in the Contemporary Diagnosis and Prognosis of Cardiac Sarcoidosis: A Comprehensive Review. Life 2023;13:1653. https://doi.org/10.3390/life13081653Kazuhiro TOUHARA, Takamune ACHIHA, Shingo TOYOTA, Shuki OKUHARA, Motohide TAKAHARA, Yuhei HOSHIKUMA, Shuhei YAMADA, Tomoaki MURAKAMI, Maki KOBAYASHI, Haruhiko KISHIMA, Internal Carotid Artery Occlusion Associated with Cardiac Sarcoidosis during the Postpartum Period Treated with Thrombectomy: A Case Report, NMC Case Report Journal. 2025 Apr 11:12:133-138. https://doi.org/10.2176/jns-nmc.2024-0264Kazuhiro TOUHARA, Takamune ACHIHA, Shingo TOYOTA, Shuki OKUHARA, Motohide TAKAHARA, Yuhei HOSHIKUMA, Shuhei YAMADA, Tomoaki MURAKAMI, Maki KOBAYASHI, Haruhiko KISHIMA, Internal Carotid Artery Occlusion Associated with Cardiac Sarcoidosis during the Postpartum Period Treated with Thrombectomy: A Case Report, NMC Case Report Journal. 2025 Apr 11:12:133-138. https://doi.org/10.2176/jns-nmc.2024-0264Javadi N., Bismee N.N., Abbas M.T., Scalia I.G., Pereyra M., Baba Ali N., Attaripour Esfahani S., Awad K., Farina J.M., Ayoub C. et al. Left Atrial Strain: State of the Art and Clinical Implications. J Pers Med . 2024 Nov 5;14(11):1093. https://doi.org/10.3390/jpm14111093Javadi N., Bismee N.N., Abbas M.T., Scalia I.G., Pereyra M., Baba Ali N., Attaripour Esfahani S., Awad K., Farina J.M., Ayoub C. et al. Left Atrial Strain: State of the Art and Clinical Implications. J Pers Med . 2024 Nov 5;14(11):1093. https://doi.org/10.3390/jpm14111093Palmiero G, Rubino M, Monda E, Caiazza M, D'Urso L, Carlomagno G, Verrillo F, Ascione R, Manganelli F, Cerciello G, De Rimini ML, Bossone E, Pacileo G, Calabrò P, Golino P, Ascione L, Caso P, Limongelli G. Global Left Ventricular Myocardial Work Efficiency in Heart Failure Patien J CardiovascEchogr. 2021 JulSep;31(3):157-164. Epub 2021 Oct 26. PMID: 34900551; PMCID: PMC8603776. https://doi.org/10.4103/jcecho.jcecho_16_21Palmiero G, Rubino M, Monda E, Caiazza M, D'Urso L, Carlomagno G, Verrillo F, Ascione R, Manganelli F, Cerciello G, De Rimini ML, Bossone E, Pacileo G, Calabrò P, Golino P, Ascione L, Caso P, Limongelli G. Global Left Ventricular Myocardial Work Efficiency in Heart Failure Patien J CardiovascEchogr. 2021 JulSep;31(3):157-164. Epub 2021 Oct 26. PMID: 34900551; PMCID: PMC8603776. https://doi.org/10.4103/jcecho.jcecho_16_21Clemmensen TS, Eiskjær H, Ladefoged B, Mikkelsen F, Sørensen J, Granstam SO, Rosengren S, Flachskampf FA, Poulsen SH. Prognostic implications of left ventricular myocardial work indices in cardiac amyloidosis. 2021 May 10; 22(6):695-704. PMID: 32529207. https://doi.org/10.1093/ehjci/jeaa097Clemmensen TS, Eiskjær H, Ladefoged B, Mikkelsen F, Sørensen J, Granstam SO, Rosengren S, Flachskampf FA, Poulsen SH. Prognostic implications of left ventricular myocardial work indices in cardiac amyloidosis. 2021 May 10; 22(6):695-704. PMID: 32529207. https://doi.org/10.1093/ehjci/jeaa097Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016 Jun 14;133(24):2404-12. https://doi.org/10.1161/CIRCULATIONAHA.116.021612Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016 Jun 14;133(24):2404-12. https://doi.org/10.1161/CIRCULATIONAHA.116.021612Томография сердца/ под ред. С.К. Тернового. – М.: ГЭОТАР-Медиа, 2018.–296 с. ISBN: 978-5-9704-4608-9 [Tomography of the heart / ed. S.K. Ternovy. – M.: GEOTAR-Media, 2018.–296 p. ISBN: 978-5-9704-4608-9]Tomography of the heart / ed. S.K. Ternovy. – M.: GEOTAR-Media, 2018.–296 p. ISBN: 978-5-9704-4608-9]Fontana M, Martinez-Naharro A, Chacko L, Rowczenio D, Gilbertson JA, Whelan CJ, Strehina S, Lane T, Moon J, Hutt DF, Kellman P, Petrie A, Hawkins PN, Gillmore JD. Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. JACC Cardiovasc Imaging. 2021 Jan;14(1):189-199. https://doi.org/10.1016/j.jcmg.2020.07.043Fontana M, Martinez-Naharro A, Chacko L, Rowczenio D, Gilbertson JA, Whelan CJ, Strehina S, Lane T, Moon J, Hutt DF, Kellman P, Petrie A, Hawkins PN, Gillmore JD. Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression. JACC Cardiovasc Imaging. 2021 Jan;14(1):189-199. https://doi.org/10.1016/j.jcmg.2020.07.043Maggialetti N., Torrente A., Lorusso G., et al. Role of Cardiovascular Magnetic Resonance in Cardiac Amyloidosis: A Narrative Review. J Pers Med. 2024;14(4):407. https://doi.org/10.3390/jpm14040407Maggialetti N., Torrente A., Lorusso G., et al. Role of Cardiovascular Magnetic Resonance in Cardiac Amyloidosis: A Narrative Review. J Pers Med. 2024;14(4):407. https://doi.org/10.3390/jpm14040407Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, Maestrini V, Barcella W, Rosmini S, Bulluck H, Sayed RH, Patel K, Mamhood S, Bucciarelli-Ducci C, Whelan CJ, Herrey AS, Lachmann HJ, Wechalekar AD, Manisty CH, Schelbert EB, Kellman P, Gillmore JD, Hawkins PN, Moon JC. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2015 Oct 20;132(16):1570-9. https://doi.org/10.1161/CIRCULATIONAHA.115.016567Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, Maestrini V, Barcella W, Rosmini S, Bulluck H, Sayed RH, Patel K, Mamhood S, Bucciarelli-Ducci C, Whelan CJ, Herrey AS, Lachmann HJ, Wechalekar AD, Manisty CH, Schelbert EB, Kellman P, Gillmore JD, Hawkins PN, Moon JC. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2015 Oct 20;132(16):1570-9. https://doi.org/10.1161/CIRCULATIONAHA.115.016567Cai S, Haghbayan H, Chan KKW, Deva DP, Jimenez-Juan L, Connelly KA, Ng MY, Yan RT, Yan AT. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis. Int J Cardiol. 2024 May 15;403:131892. https://doi.org/10.1016/j.ijcard.2024.131892Cai S, Haghbayan H, Chan KKW, Deva DP, Jimenez-Juan L, Connelly KA, Ng MY, Yan RT, Yan AT. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis. Int J Cardiol. 2024 May 15;403:131892. https://doi.org/10.1016/j.ijcard.2024.131892Martinez-Naharro A, Patel R, Kotecha T, Karia N, Ioannou A, Petrie A, Chacko LA, Razvi Y, Ravichandran S, Brown J, Law S, Quarta C, Mahmood S, Wisniowski B, Pica S, Sachchithanantham S, Lachmann HJ, Moon JC, Knight DS, Whelan C, Venneri L, Xue H, Kellman P, Gillmore JD, Hawkins PN, Wechalekar AD, Fontana M. Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment. Eur Heart J. 2022 Dec 1;43(45):4722-4735. https://doi.org/10.1093/eurheartj/ehac363Martinez-Naharro A, Patel R, Kotecha T, Karia N, Ioannou A, Petrie A, Chacko LA, Razvi Y, Ravichandran S, Brown J, Law S, Quarta C, Mahmood S, Wisniowski B, Pica S, Sachchithanantham S, Lachmann HJ, Moon JC, Knight DS, Whelan C, Venneri L, Xue H, Kellman P, Gillmore JD, Hawkins PN, Wechalekar AD, Fontana M. Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment. Eur Heart J. 2022 Dec 1;43(45):4722-4735. https://doi.org/10.1093/eurheartj/ehac363Pan JA, Kerwin MJ, Salerno M. Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis. JACC Cardiovasc Imaging. 2020 Jun;13(6):1299-1310. https://doi.org/10.1016/j.jcmg.2020.03.010Pan JA, Kerwin MJ, Salerno M. Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis. JACC Cardiovasc Imaging. 2020 Jun;13(6):1299-1310. https://doi.org/10.1016/j.jcmg.2020.03.010Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013 Apr;6(4):48897. https://doi.org/10.1016/j.jcmg.2012.11.013Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013 Apr;6(4):48897. https://doi.org/10.1016/j.jcmg.2012.11.013Lavall D, Vosshage NH, Geßner R, Stöbe S, Ebel S, Denecke T, Hagendorff A, Laufs U. Native T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophy. Clin Res Cardiol. 2023 Mar;112(3):334-342. https://doi.org/10.1007/s00392-022-02005-2Lavall D, Vosshage NH, Geßner R, Stöbe S, Ebel S, Denecke T, Hagendorff A, Laufs U. Native T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophy. Clin Res Cardiol. 2023 Mar;112(3):334-342. https://doi.org/10.1007/s00392-022-02005-2Martinez-Naharro A, Patel R, Kotecha T, Karia N, Ioannou A, Petrie A, Chacko LA, Razvi Y, Ravichandran S, Brown J, Law S, Quarta C, Mahmood S, Wisniowski B, Pica S, Sachchithanantham S, Lachmann HJ, Moon JC, Knight DS, Whelan C, Venneri L, Xue H, Kellman P, Gillmore JD, Hawkins PN, Wechalekar AD, Fontana M. Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment. Eur Heart J. 2022 Dec 1;43(45):4722-4735. https://doi.org/10.1093/eurheartj/ehac363Martinez-Naharro A, Patel R, Kotecha T, Karia N, Ioannou A, Petrie A, Chacko LA, Razvi Y, Ravichandran S, Brown J, Law S, Quarta C, Mahmood S, Wisniowski B, Pica S, Sachchithanantham S, Lachmann HJ, Moon JC, Knight DS, Whelan C, Venneri L, Xue H, Kellman P, Gillmore JD, Hawkins PN, Wechalekar AD, Fontana M. Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment. Eur Heart J. 2022 Dec 1;43(45):4722-4735. https://doi.org/10.1093/eurheartj/ehac363Martinez-Naharro A, Baksi AJ, Hawkins PN, Fontana M. Diagnostic imaging of cardiac amyloidosis. Nat Rev Cardiol. 2020 Jul;17(7):413-426. https://doi.org/10.1038/s41569-020-0334-7Martinez-Naharro A, Baksi AJ, Hawkins PN, Fontana M. Diagnostic imaging of cardiac amyloidosis. Nat Rev Cardiol. 2020 Jul;17(7):413-426. https://doi.org/10.1038/s41569-020-0334-7Ridouani F, Damy T, Tacher V, Derbel H, Legou F, Sifaoui I, Audureau E, Bodez D, Rahmouni A, Deux JF. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. J Cardiovasc Magn Reson. 2018 Aug 16;20(1):58. https://doi.org/10.1186/s12968-018-0478-3Ridouani F, Damy T, Tacher V, Derbel H, Legou F, Sifaoui I, Audureau E, Bodez D, Rahmouni A, Deux JF. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. J Cardiovasc Magn Reson. 2018 Aug 16;20(1):58. https://doi.org/10.1186/s12968-018-0478-3Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, BacchiReggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009 Sep 29;120(13):1203-12. https://doi.org/10.1161/CIRCULATIONAHA.108.843334Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, BacchiReggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009 Sep 29;120(13):1203-12. https://doi.org/10.1161/CIRCULATIONAHA.108.843334Yilmaz A, Bauersachs J, Bengel F, Büchel R, Kindermann I, Klingel K, et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021;110(4):479-506.doi.org/10,1007/s00392-020-01799-3Yilmaz A, Bauersachs J, Bengel F, Büchel R, Kindermann I, Klingel K, et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021;110(4):479-506.doi.org/10,1007/s00392-020-01799-3Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, Nair AP, Nativi-Nicolau J, Ruberg FL; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020 Jul 7;142(1):e7e22. https://doi.org/10.1161/CIR.0000000000000792. Epub 2020 Jun 1. Erratum in: Circulation. 2021 Jul 6;144(1):e10, https://doi.org/10.1161/CIR.0000000000000997. Erratum in: Circulation. 2021 Jul 6;144(1):e11. https://doi.org/10.1161/CIR.0000000000000998Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, Nair AP, Nativi-Nicolau J, Ruberg FL; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020 Jul 7;142(1):e7e22. https://doi.org/10.1161/CIR.0000000000000792. Epub 2020 Jun 1. Erratum in: Circulation. 2021 Jul 6;144(1):e10, https://doi.org/10.1161/CIR.0000000000000997. Erratum in: Circulation. 2021 Jul 6;144(1):e11. https://doi.org/10.1161/CIR.0000000000000998Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018;25(4):215–9. https://doi.org/10.1080/13506129.2018.1549825Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018;25(4):215–9. https://doi.org/10.1080/13506129.2018.1549825Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study. Ann Med. 2008;40(3):2329. https://doi.org/10.1080/07853890701842988Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study. Ann Med. 2008;40(3):2329. https://doi.org/10.1080/07853890701842988Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization. J Nucl Cardiol. 2019; Available from: https://doi.org/10.1007/s12350-019-01761-5Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization. J Nucl Cardiol. 2019; Available from: https://doi.org/10.1007/s12350-019-01761-5Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891. https://doi.org/10.1016/j.jacc.2019.04.003Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891. https://doi.org/10.1016/j.jacc.2019.04.003Park GY, Jamerlan A, Shim KH, An SSA. Diagnostic and Treatment Approaches Involving Transthyretin in Amyloidogenic Diseases. Int J Mol Sci. 2019 Jun 18;20(12):2982. https://doi.org/10.3390/ijms20122982.Park GY, Jamerlan A, Shim KH, An SSA. Diagnostic and Treatment Approaches Involving Transthyretin in Amyloidogenic Diseases. Int J Mol Sci. 2019 Jun 18;20(12):2982. https://doi.org/10.3390/ijms20122982.Conceição I, González-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, Amass L. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016 Mar;21(1):5-9. https://doi.org/10.1111/jns.12153Conceição I, González-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, Amass L. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016 Mar;21(1):5-9. https://doi.org/10.1111/jns.12153Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, Broglio L, Granieri E, Lauria G. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008 Jul;131(Pt 7):1912-25. https://doi.org/10.1093/brain/awn093. Epub 2008 Jun 4. PMID: 18524793; PMCID: PMC2442424Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, Broglio L, Granieri E, Lauria G. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008 Jul;131(Pt 7):1912-25. https://doi.org/10.1093/brain/awn093. Epub 2008 Jun 4. PMID: 18524793; PMCID: PMC2442424Lobato L, Beirão I, Silva M, Bravo F, Silvestre F, Guimarães S, Sousa A, Noël LH, Sequeiros J. Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy. Nephrol Dial Transplant. 2003 Mar;18(3):5328. https://doi.org/10.1093/ndt/18.3.532.Lobato L, Beirão I, Silva M, Bravo F, Silvestre F, Guimarães S, Sousa A, Noël LH, Sequeiros J. Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy. Nephrol Dial Transplant. 2003 Mar;18(3):5328. https://doi.org/10.1093/ndt/18.3.532.Papagianni A, Ihne S, Zeller D, Morbach C, Üçeyler N, Sommer C. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type. Amyloid. 2022 Mar;29(1):14-22. https://doi.org/10.1080/13506129.2021.1976751 . Epub 2021 Oct 11. PMID: 34632904.Papagianni A, Ihne S, Zeller D, Morbach C, Üçeyler N, Sommer C. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type. Amyloid. 2022 Mar;29(1):14-22. https://doi.org/10.1080/13506129.2021.1976751 . Epub 2021 Oct 11. PMID: 34632904.Sakashita N, Ando Y, Jinnouchi K, Yoshimatsu M, Terazaki H, Obayashi K, Takeya M. Familial amyloidotic polyneuropathy (ATTR Val30Met) with widespread cerebral amyloid angiopathy and lethal cerebral hemorrhage. Pathol Int. 2001 Jun;51(6):476-80, https://doi.org/10.1046/j.1440-1827.2001.01228.x.Sakashita N, Ando Y, Jinnouchi K, Yoshimatsu M, Terazaki H, Obayashi K, Takeya M. Familial amyloidotic polyneuropathy (ATTR Val30Met) with widespread cerebral amyloid angiopathy and lethal cerebral hemorrhage. Pathol Int. 2001 Jun;51(6):476-80, https://doi.org/10.1046/j.1440-1827.2001.01228.x.Ikeda SI. [Cerebral amyloid angiopathy with familial transthyretinderived oculoleptomeningeal amyloidosis]. Brain Nerve. 2013 Jul;65(7):831-42. Japanese.Ikeda SI. [Cerebral amyloid angiopathy with familial transthyretinderived oculoleptomeningeal amyloidosis]. Brain Nerve. 2013 Jul;65(7):831-42. Japanese.Golbus JR, Wells JM, Dickinson MG, Hummel SL. Importance of Genetic Testing in the Diagnosis of Transthyretin Cardiac Amyloidosis. Am J Med. 2018;131(7):e303-4. https://doi.org/10.1016/j.amjmed.2018.02.005Golbus JR, Wells JM, Dickinson MG, Hummel SL. Importance of Genetic Testing in the Diagnosis of Transthyretin Cardiac Amyloidosis. Am J Med. 2018;131(7):e303-4. https://doi.org/10.1016/j.amjmed.2018.02.005Obici L, Kuks JB, Buades J, Adams D, Suhr OB, Coelho T, et al. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol. 2016;29:S27–35. https://doi.org/10.1097/wco.0000000000000290Obici L, Kuks JB, Buades J, Adams D, Suhr OB, Coelho T, et al. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol. 2016;29:S27–35. https://doi.org/10.1097/wco.0000000000000290Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3,3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15(11):1289-98. https://doi.org/10.1093/ehjci/jeu107Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3,3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15(11):1289-98. https://doi.org/10.1093/ehjci/jeu107Резник Е.В., Нгуен Т.Л., Степанова Е.А., Устюжанин Д.В., Никитин И.Г. Амилоидоз сердца: взгляд терапевта и кардиолога. Архивъ внутренней медицины. 2020;10(6):430-457. https://doi.org/10.20514/2226-6704-2020-10-6-430-457Reznik E.V., Nguyen T.L., Stepanova E.A., Ustyuzhanin D.V., Nikitin I.G. Cardiac Amyloidosis: Internist and Cardiologist Insight. The Russian Archives of Internal Medicine. 2020;10(6):430-457. https://doi.org/10.20514/2226-6704-2020-10-6-430-457]Poterucha TJ, Elias P, Bokhari S, Einstein AJ, DeLuca A, Kinkhabwala M, et al. Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution. JACC Cardiovasc Imaging. 2021;14(6):1221–1231. https://doi.org/10.1016/j.jcmg.2020.08.027Poterucha TJ, Elias P, Bokhari S, Einstein AJ, DeLuca A, Kinkhabwala M, et al. Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution. JACC Cardiovasc Imaging. 2021;14(6):1221–1231. https://doi.org/10.1016/j.jcmg.2020.08.027Gertz M, Adams D, Ando Y, Beirão JM, Bokhari S, Coelho T, et al. Avoiding misdiagnosis: Expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Fam Pract. 2020;21(1):1-12. https://doi.org/10.1186/s12875-020-01252-4Gertz M, Adams D, Ando Y, Beirão JM, Bokhari S, Coelho T, et al. Avoiding misdiagnosis: Expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Fam Pract. 2020;21(1):1-12. https://doi.org/10.1186/s12875-020-01252-4Sprangers B, Claes K, Evenepoel P, Kuypers D, Poesen K, Delforge M, et al. Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients. Kidney Int Reports. 2020;5(5):627–31. Available from: https://doi.org/10.1016/j.ekir.2020.01.019Sprangers B, Claes K, Evenepoel P, Kuypers D, Poesen K, Delforge M, et al. Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients. Kidney Int Reports. 2020;5(5):627–31. Available from: https://doi.org/10.1016/j.ekir.2020.01.019Bonderman D, Pölzl G, Ablasser K, Agis H, Aschauer S, AuerGrumbach M, et al. Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wien Klin Wochenschr. 2020;132(23–24):742–761. https://doi.org/10.1007/s00508-020-01781-zBonderman D, Pölzl G, Ablasser K, Agis H, Aschauer S, AuerGrumbach M, et al. Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wien Klin Wochenschr. 2020;132(23–24):742–761. https://doi.org/10.1007/s00508-020-01781-zDispenzieri A, Kyle R, Merlini G et al. International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23:215-224. https://doi.org/10.1038/leu.2008.307Dispenzieri A, Kyle R, Merlini G et al. International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23:215-224. https://doi.org/10.1038/leu.2008.307Rahel S, Flammer Andreas J, Sabine G et al. Expert recommendation from the swiss amyloidosis network (SAN) for systemic ALamyloidosis. Swiss Med Wkly . 2020 Dec 5:150:w20364. https://doi.org/10.4414/smw.2020.20364Rahel S, Flammer Andreas J, Sabine G et al. Expert recommendation from the swiss amyloidosis network (SAN) for systemic ALamyloidosis. Swiss Med Wkly . 2020 Dec 5:150:w20364. https://doi.org/10.4414/smw.2020.20364Quarta, CC, Gonzalez-Lopez E, Gilbertson JA., et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J 2017;38(24):1905-1908. https://doi.org/10.1093/eurheartj/ehx047Quarta, CC, Gonzalez-Lopez E, Gilbertson JA., et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J 2017;38(24):1905-1908. https://doi.org/10.1093/eurheartj/ehx047Kimmich C, Schönland S, Kräker S et al. Amyloid in bone marrow smears in systemic light-chain amyloidosis. Amyloid 2017; 24(1):52-59. https://doi.org/10.1080/13506129.2017.1314959Kimmich C, Schönland S, Kräker S et al. Amyloid in bone marrow smears in systemic light-chain amyloidosis. Amyloid 2017; 24(1):52-59. https://doi.org/10.1080/13506129.2017.1314959Muchtar E, Dispenzieri A, Lacy MQ et al. Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Ann Med 2017; 49(7):545-551. https://doi.org/10.1080/07853890.2017.1304649Muchtar E, Dispenzieri A, Lacy MQ et al. Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Ann Med 2017; 49(7):545-551. https://doi.org/10.1080/07853890.2017.1304649Gertz MA, Comenzo R, Falk RH et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005; 79(4):319-328. https://doi.org/10.1002/ajh.20381Gertz MA, Comenzo R, Falk RH et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005; 79(4):319-328. https://doi.org/10.1002/ajh.20381Phull P, Sanchorawala V, Connors LH et al. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid 2018; 25(1):62-67. https://doi.org/10.1080/13506129.2018.1436048Phull P, Sanchorawala V, Connors LH et al. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid 2018; 25(1):62-67. https://doi.org/10.1080/13506129.2018.1436048Coelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, Kelly JW, Maurer MS, Planté-Bordeneuve V, Labaudinière R, Mundayat R, Riley S, Lombardo I, Huertas P. Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther. 2016 Jun;5(1):1-25. https://doi.org/10.1007/s40120-016-0040-хCoelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, Kelly JW, Maurer MS, Planté-Bordeneuve V, Labaudinière R, Mundayat R, Riley S, Lombardo I, Huertas P. Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther. 2016 Jun;5(1):1-25. https://doi.org/10.1007/s40120-016-0040-хMaurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007–16. https://doi.org/10.1056/NEJMoa1805689Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007–16. https://doi.org/10.1056/NEJMoa1805689Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Patterson TA, et al. Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Am J Cardiol. 2021;141:98–105. https://doi.org/10.1016/j.amjcard.2020.10.066Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Patterson TA, et al. Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). Am J Cardiol. 2021;141:98–105. https://doi.org/10.1016/j.amjcard.2020.10.066Badr Eslam R, Öztürk B, Rettl R, Capelle CDJ, Qin H, Binder C, et al. Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy. Circ Heart Fail. 2022;15(7):e008381. https://doi.org/10.1161/CIRCHEARTFAILURE.121.008381Badr Eslam R, Öztürk B, Rettl R, Capelle CDJ, Qin H, Binder C, et al. Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy. Circ Heart Fail. 2022;15(7):e008381. https://doi.org/10.1161/CIRCHEARTFAILURE.121.008381Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, Ebede B, Gundapaneni B, Li B, Sultan MB, Shah SJ. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. Circ Heart Fail. 2022 Jan;15(1):e008193. https://doi.org/10.1161/circheartfailure.120.008193Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, Ebede B, Gundapaneni B, Li B, Sultan MB, Shah SJ. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. Circ Heart Fail. 2022 Jan;15(1):e008193. https://doi.org/10.1161/circheartfailure.120.008193Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and longterm extension study. Eur J Heart Fail. 2021;23(2):277-85. https:// doi.org/10.1002/ejhf.2027Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and longterm extension study. Eur J Heart Fail. 2021;23(2):277-85. https:// doi.org/10.1002/ejhf.2027Шошина А.А., Аншелес А.А., Насонова С.Н., Жиров И.В., Сергиенко В.Б., Терещенко С. Н. Роль сцинтиграфии миокарда с 99mTc-пирофосфатом в оценке эффективности терапии тафамидисом на примере серии клинических случаев. Российский кардиологический журнал. 2025;30(1):6200. https://doi.org/10.15829/1560-4071-2025-6200Шошина А.А., Аншелес А.А., Насонова С.Н., Жиров И.В., Сергиенко В.Б., Терещенко С. Н. Роль сцинтиграфии миокарда с 99mTc-пирофосфатом в оценке эффективности терапии тафамидисом на примере серии клинических случаев. Российский кардиологический журнал. 2025;30(1):6200. https://doi.org/10.15829/1560-4071-2025-6200Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, Grogan M, Hanna M, Hoffman J, Masri A, et al. ; ATTRibute-CM Investigators. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390:132-142. https://doi.org/10.1056/NEJMoa2305434Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, Grogan M, Hanna M, Hoffman J, Masri A, et al. ; ATTRibute-CM Investigators. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390:132-142. https://doi.org/10.1056/NEJMoa2305434Judge DP, Gillmore JD, Alexander KM, Ambardekar AV, Cappelli F, Fontana M, García-Pavía P, Grodin JL, Grogan M, Hanna M, Masri A, Nativi-Nicolau J, Obici L, Hvitfeldt Poulsen S, Sarswat N, Shah K, Soman P, Lystig T, Cao X, Wang K, Pecoraro ML, Tamby JF, Katz L, Sinha U, Fox JC, Maurer MS. Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Circulation. 2025 Mar 4;151(9):601-611. https://doi.org/10.1161/CIRCULATIONAHA.124.072771Judge DP, Gillmore JD, Alexander KM, Ambardekar AV, Cappelli F, Fontana M, García-Pavía P, Grodin JL, Grogan M, Hanna M, Masri A, Nativi-Nicolau J, Obici L, Hvitfeldt Poulsen S, Sarswat N, Shah K, Soman P, Lystig T, Cao X, Wang K, Pecoraro ML, Tamby JF, Katz L, Sinha U, Fox JC, Maurer MS. Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Circulation. 2025 Mar 4;151(9):601-611. https://doi.org/10.1161/CIRCULATIONAHA.124.072771Razvi Y, Judge DP, Martinez-Naharro A, Ioannou A, Venneri L, Patel R, Gillmore JD, Kellman P, Edwards L, Taubel J, Du J, Tamby JF, Castaño A, Siddhanti S, Katz L, Fox JC, Fontana M. Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy. Circ Heart Fail. 2024 Dec;17(12):e012135. https://doi.org/10.1161/CIRCHEARTFAILURE.124.012135Razvi Y, Judge DP, Martinez-Naharro A, Ioannou A, Venneri L, Patel R, Gillmore JD, Kellman P, Edwards L, Taubel J, Du J, Tamby JF, Castaño A, Siddhanti S, Katz L, Fox JC, Fontana M. Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy. Circ Heart Fail. 2024 Dec;17(12):e012135. https://doi.org/10.1161/CIRCHEARTFAILURE.124.012135Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J, Bettencourt BR, Geissler M, Butler JS, Sehgal A, Meyers RE, Chen Q, Borland T, Hutabarat RM, Clausen VA, Alvarez R, Fitzgerald K, Gamba-Vitalo C, Nochur SV, Vaishnaw AK, Sah DW, Gollob JA, Suhr OB. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013 Aug 29;369(9):81929. https://doi.org/10.1056/NEJMoa1208760Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J, Bettencourt BR, Geissler M, Butler JS, Sehgal A, Meyers RE, Chen Q, Borland T, Hutabarat RM, Clausen VA, Alvarez R, Fitzgerald K, Gamba-Vitalo C, Nochur SV, Vaishnaw AK, Sah DW, Gollob JA, Suhr OB. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013 Aug 29;369(9):81929. https://doi.org/10.1056/NEJMoa1208760Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):11-21. https://doi.org/10.1056/NEJMoa1716153Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):11-21. https://doi.org/10.1056/NEJMoa1716153Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH 3rd, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation. 2019 Jan 22;139(4):431-443. https://doi.org/10.1161/CIRCULATIONAHA.118.035831Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH 3rd, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation. 2019 Jan 22;139(4):431-443. https://doi.org/10.1161/CIRCULATIONAHA.118.035831Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, Hung RR, Gottlieb RL, Damy T, González-Duarte A, Sarswat N, Sekijima Y, Tahara N, Taylor MS, Kubanek M, Donal E, Palecek T, Tsujita K, Tang WHW, Yu WC, Obici L, Simões M, Fernandes F, Poulsen SH, Diemberger I, Perfetto F, Solomon SD, Di Carli M, Badri P, White MT, Chen J, Yureneva E, Sweetser MT, Jay PY, Garg PP, Vest J, Gillmore JD; APOLLO-B Trial Investigators. Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med. 2023 Oct 26;389(17):1553-1565. PMID: 37888916. PMCID: PMC10757426. https://doi.org/10.1056/NEJMoa2300757Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, Hung RR, Gottlieb RL, Damy T, González-Duarte A, Sarswat N, Sekijima Y, Tahara N, Taylor MS, Kubanek M, Donal E, Palecek T, Tsujita K, Tang WHW, Yu WC, Obici L, Simões M, Fernandes F, Poulsen SH, Diemberger I, Perfetto F, Solomon SD, Di Carli M, Badri P, White MT, Chen J, Yureneva E, Sweetser MT, Jay PY, Garg PP, Vest J, Gillmore JD; APOLLO-B Trial Investigators. Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med. 2023 Oct 26;389(17):1553-1565. PMID: 37888916. PMCID: PMC10757426. https://doi.org/10.1056/NEJMoa2300757Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, Berk JL, González-Duarte A, Gillmore JD, Low SC, Sekijima Y, Obici L, Chen C, Badri P, Arum SM, Vest J, Polydefkis M; HELIOS-A Collaborators. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023 Mar;30(1):1-9. https://doi.org/10.1080/13506129.2022.2091985Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, Berk JL, González-Duarte A, Gillmore JD, Low SC, Sekijima Y, Obici L, Chen C, Badri P, Arum SM, Vest J, Polydefkis M; HELIOS-A Collaborators. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023 Mar;30(1):1-9. https://doi.org/10.1080/13506129.2022.2091985Garcia-Pavia P, Grogan M, Kale P, Berk JL, Maurer MS, Conceição I, Di Carli M, Solomon SD, Chen C, Yureneva E, Vest J, Gillmore JD. Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy. Eur J Heart Fail. 2024 Feb;26(2):397-410. https://doi.org/10.1002/ejhf.3138Garcia-Pavia P, Grogan M, Kale P, Berk JL, Maurer MS, Conceição I, Di Carli M, Solomon SD, Chen C, Yureneva E, Vest J, Gillmore JD. Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy. Eur J Heart Fail. 2024 Feb;26(2):397-410. https://doi.org/10.1002/ejhf.3138Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, Damy T, Garcia-Pavia P, Taubel J, Solomon SD, Sheikh FH, Tahara N, González-Costello J, Tsujita K, Morbach C, Pozsonyi Z, Petrie MC, Delgado D, Van der Meer P, Jabbour A, Bondue A, Kim D, Azevedo O, Hvitfeldt Poulsen S, Yilmaz A, Jankowska EA, Algalarrondo V, Slugg A, Garg PP, Boyle KL, Yureneva E, Silliman N, Yang L, Chen J, Eraly SA, Vest J, Maurer MS; HELIOS-B Trial Investigators. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2025 Jan 2;392(1):33-44. https://doi.org/10.1056/NEJMoa2409134Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, Damy T, Garcia-Pavia P, Taubel J, Solomon SD, Sheikh FH, Tahara N, González-Costello J, Tsujita K, Morbach C, Pozsonyi Z, Petrie MC, Delgado D, Van der Meer P, Jabbour A, Bondue A, Kim D, Azevedo O, Hvitfeldt Poulsen S, Yilmaz A, Jankowska EA, Algalarrondo V, Slugg A, Garg PP, Boyle KL, Yureneva E, Silliman N, Yang L, Chen J, Eraly SA, Vest J, Maurer MS; HELIOS-B Trial Investigators. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2025 Jan 2;392(1):33-44. https://doi.org/10.1056/NEJMoa2409134Witteles RM, Garcia-Pavia P, Damy T, Grogan M, Sheikh FH, Morbach C, Bender S, Exter J, Eraly SA, Fontana M. Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B. J Am Coll Cardiol. 2025 Apr 30:S0735-1097(25)06170-4. https://doi.org/10.1016/j.jacc.2025.04.008Witteles RM, Garcia-Pavia P, Damy T, Grogan M, Sheikh FH, Morbach C, Bender S, Exter J, Eraly SA, Fontana M. Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B. J Am Coll Cardiol. 2025 Apr 30:S0735-1097(25)06170-4. https://doi.org/10.1016/j.jacc.2025.04.008Coelho T, Marques W Jr, Dasgupta NR, Chao CC, Parman Y, França MC Jr, Guo YC, Wixner J, Ro LS, Calandra CR, Kowacs PA, Berk JL, Obici L, Barroso FA, Weiler M, Conceição I, Jung SW, Buchele G, Brambatti M, Chen J, Hughes SG, Schneider E, Viney NJ, Masri A, Gertz MR, Ando Y, Gillmore JD, Khella S, Dyck PJB, Waddington Cruz M; NEURO-TTRansform Investigators. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. JAMA. 2023 Oct 17;330(15):1448-1458. https://doi.org/10.1001/jama.2023.18688Coelho T, Marques W Jr, Dasgupta NR, Chao CC, Parman Y, França MC Jr, Guo YC, Wixner J, Ro LS, Calandra CR, Kowacs PA, Berk JL, Obici L, Barroso FA, Weiler M, Conceição I, Jung SW, Buchele G, Brambatti M, Chen J, Hughes SG, Schneider E, Viney NJ, Masri A, Gertz MR, Ando Y, Gillmore JD, Khella S, Dyck PJB, Waddington Cruz M; NEURO-TTRansform Investigators. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. JAMA. 2023 Oct 17;330(15):1448-1458. https://doi.org/10.1001/jama.2023.18688Masri A, Maurer MS, Claggett BL, Kulac I, Waddington Cruz M, Conceição I, Weiler M, Berk JL, Gertz M, Gillmore JD, Rush S, Chen J, Zhou W, Kwoh J, Duran JM, Tsimikas S, Solomon SD. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis. J Card Fail. 2024 Aug;30(8):973-980, https://doi.org/10.1016/j.cardfail.2023.11.016Masri A, Maurer MS, Claggett BL, Kulac I, Waddington Cruz M, Conceição I, Weiler M, Berk JL, Gertz M, Gillmore JD, Rush S, Chen J, Zhou W, Kwoh J, Duran JM, Tsimikas S, Solomon SD. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis. J Card Fail. 2024 Aug;30(8):973-980, https://doi.org/10.1016/j.cardfail.2023.11.016Brito D, Albrecht FC, de Arenaza DP, Bart N, Better N, Carvajal-Juarez I, Conceição I, Damy T, Dorbala S, Fidalgo JC, Garcia-Pavia P, Ge J, Gillmore JD, Grzybowski J, Obici L, Piñero D, Rapezzi C, Ueda M, Pinto FJ. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Glob Heart. 2023 Oct 26;18(1):59. https://doi.org/10.5334/gh.1262Brito D, Albrecht FC, de Arenaza DP, Bart N, Better N, Carvajal-Juarez I, Conceição I, Damy T, Dorbala S, Fidalgo JC, Garcia-Pavia P, Ge J, Gillmore JD, Grzybowski J, Obici L, Piñero D, Rapezzi C, Ueda M, Pinto FJ. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Glob Heart. 2023 Oct 26;18(1):59. https://doi.org/10.5334/gh.1262Nuvolone M, Nevon A, Merlini G. Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis. BioDrugs. 2022 Sep;36(5):591-608. https://doi.org/10.1007/s40259-022-00550-wNuvolone M, Nevon A, Merlini G. Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis. BioDrugs. 2022 Sep;36(5):591-608. https://doi.org/10.1007/s40259-022-00550-wGarcia-Pavia P, Aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV, Mercuri MF, Michalon A, Frost RJA, Grimm J, Nitsch RM, Hock C, Kahr PC, Damy T. Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. N Engl J Med. 2023 Jul 20;389(3):239-250. https://doi.org/10.1056/NEJMoa2303765Garcia-Pavia P, Aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV, Mercuri MF, Michalon A, Frost RJA, Grimm J, Nitsch RM, Hock C, Kahr PC, Damy T. Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. N Engl J Med. 2023 Jul 20;389(3):239-250. https://doi.org/10.1056/NEJMoa2303765Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, Seitzer J, O'Connell D, Walsh KR, Wood K, Phillips J, Xu Y, Amaral A, Boyd AP, Cehelsky JE, McKee MD, Schiermeier A, Harari O, Murphy A, Kyratsous CA, Zambrowicz B, Soltys R, Gutstein DE, Leonard J, Sepp-Lorenzino L, Lebwohl D. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021 Aug 5;385(6):493-502. https://doi.org/10.1056/NEJMoa2107454Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, Seitzer J, O'Connell D, Walsh KR, Wood K, Phillips J, Xu Y, Amaral A, Boyd AP, Cehelsky JE, McKee MD, Schiermeier A, Harari O, Murphy A, Kyratsous CA, Zambrowicz B, Soltys R, Gutstein DE, Leonard J, Sepp-Lorenzino L, Lebwohl D. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021 Aug 5;385(6):493-502. https://doi.org/10.1056/NEJMoa2107454Kotit S. Lessons from the first-in-human in vivo CRISPR/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy. Glob Cardiol Sci Pract. 2023 Jan 30;2023(1):e202304. https://doi.org/10.21542/gcsp.2023.4Kotit S. Lessons from the first-in-human in vivo CRISPR/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy. Glob Cardiol Sci Pract. 2023 Jan 30;2023(1):e202304. https://doi.org/10.21542/gcsp.2023.4Sperry BW, Hanna M, Shah SJ, Jaber WA, Spertus JA. Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT. JACC Heart Fail. 2021 Nov;9(11):795-802. https://doi.org/10.1016/j.jchf.2021.06.007Sperry BW, Hanna M, Shah SJ, Jaber WA, Spertus JA. Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT. JACC Heart Fail. 2021 Nov;9(11):795-802. https://doi.org/10.1016/j.jchf.2021.06.007Ioannou A, Massa P, Patel RK, Razvi Y, Porcari A, Rauf MU, Jiang A, Cabras G, Filisetti S, Bolhuis RE, Bandera F, Venneri L, MartinezNaharro A, Law S, Kotecha T, Virsinskaite R, Knight DS, Emdin M, Petrie A, Lachmann H, Wechelakar A, Petrie M, Hughes A, Freemantle N, Hawkins PN, Whelan C, McMurray JJV, Gillmore JD, Fontana M. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023 Aug 14;44(31):2893-2907. https:// doi.org/10.1093/eurheartj/ehad347. Erratum in: Eur Heart J. 2024 Apr 7;45(14):1251. https://doi.org/10.1093/eurheartj/ehae140Ioannou A, Massa P, Patel RK, Razvi Y, Porcari A, Rauf MU, Jiang A, Cabras G, Filisetti S, Bolhuis RE, Bandera F, Venneri L, MartinezNaharro A, Law S, Kotecha T, Virsinskaite R, Knight DS, Emdin M, Petrie A, Lachmann H, Wechelakar A, Petrie M, Hughes A, Freemantle N, Hawkins PN, Whelan C, McMurray JJV, Gillmore JD, Fontana M. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023 Aug 14;44(31):2893-2907. https:// doi.org/10.1093/eurheartj/ehad347. Erratum in: Eur Heart J. 2024 Apr 7;45(14):1251. https://doi.org/10.1093/eurheartj/ehae140Dobner S, Bernhard B, Asatryan B, Windecker S, Stortecky S, Pilgrim T, Gräni C, Hunziker L. SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin. ESC Heart Fail. 2023 Feb;10(1):397-404. https://doi.org/10.1002/ehf2.14188Dobner S, Bernhard B, Asatryan B, Windecker S, Stortecky S, Pilgrim T, Gräni C, Hunziker L. SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin. ESC Heart Fail. 2023 Feb;10(1):397-404. https://doi.org/10.1002/ehf2.14188Zampieri M, Argirò A, Allinovi M, Perfetto F, Cappelli F. SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series. Intern Emerg Med. 2022 Jun;17(4):1243-1245. https://doi.org/10.1007/s11739-022-02944-8Zampieri M, Argirò A, Allinovi M, Perfetto F, Cappelli F. SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series. Intern Emerg Med. 2022 Jun;17(4):1243-1245. https://doi.org/10.1007/s11739-022-02944-8Lang FM, Teruya S, Weinsaft A, Cuomo M, Santos AM, Nalbandian A, Bampatsias D, Maurer MS. Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short-term efficacy and safety. Eur J Heart Fail. 2024 Apr;26(4):938-947. https://doi.org/10.1002/ejhf.3198Lang FM, Teruya S, Weinsaft A, Cuomo M, Santos AM, Nalbandian A, Bampatsias D, Maurer MS. Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short-term efficacy and safety. Eur J Heart Fail. 2024 Apr;26(4):938-947. https://doi.org/10.1002/ejhf.3198Porcari A, Cappelli F, Nitsche C, Tomasoni D, Sinigiani G, Longhi S, Bordignon L, Masri A, Serenelli M, Urey M, Musumeci B, Cipriani A, Canepa M, Badr-Eslam R, Kronberger C, Chimenti C, Zampieri M, Allegro V, Razvi Y, Patel R, Ioannou A, Rauf MU, Petrie A, Whelan C, Emdin M, Metra M, Merlo M, Sinagra G, Hawkins PN, Solomon SD, Gillmore JD, Fontana M. SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2024 Jun 18;83(24):2411-2422. https://doi.org/10.1016/j.jacc.2024.03.429Porcari A, Cappelli F, Nitsche C, Tomasoni D, Sinigiani G, Longhi S, Bordignon L, Masri A, Serenelli M, Urey M, Musumeci B, Cipriani A, Canepa M, Badr-Eslam R, Kronberger C, Chimenti C, Zampieri M, Allegro V, Razvi Y, Patel R, Ioannou A, Rauf MU, Petrie A, Whelan C, Emdin M, Metra M, Merlo M, Sinagra G, Hawkins PN, Solomon SD, Gillmore JD, Fontana M. SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2024 Jun 18;83(24):2411-2422. https://doi.org/10.1016/j.jacc.2024.03.429Schwegel N, Toferer C, Zach DK, Santner V, Höller V, Lugitsch J, Wallner M, Gollmer J, Aziz F, von Lewinski D, Kolesnik E, Ablasser K, Zirlik A, Sourij H, Verheyen N. Impact of SGLT2-Inhibitor Therapy on Survival in Patients with Transthyretin Amyloid Cardiomyopathy: Analysis of a Prospective Registry Study. J Clin Med. 2024 Oct 8;13(19):5966. https://doi.org/10.3390/jcm13195966Schwegel N, Toferer C, Zach DK, Santner V, Höller V, Lugitsch J, Wallner M, Gollmer J, Aziz F, von Lewinski D, Kolesnik E, Ablasser K, Zirlik A, Sourij H, Verheyen N. Impact of SGLT2-Inhibitor Therapy on Survival in Patients with Transthyretin Amyloid Cardiomyopathy: Analysis of a Prospective Registry Study. J Clin Med. 2024 Oct 8;13(19):5966. https://doi.org/10.3390/jcm13195966Byer SH, Sivamurugan A, Grewal US, Fradley MG, Dominic P. Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy. Am J Cardiol. 2025 May 15;243:15-18. https://doi.org/10.1016/j.amjcard.2025.01.012Byer SH, Sivamurugan A, Grewal US, Fradley MG, Dominic P. Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy. Am J Cardiol. 2025 May 15;243:15-18. https://doi.org/10.1016/j.amjcard.2025.01.012Karakasis P, Theofilis P, Patoulias D, Schuermans A, Vlachakis PK, Klisic A, Rizzo M, Fragakis N. Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: Systematic review and meta-analysis. Eur J Clin Invest. 2025 Jun;55(6):e14392. https://doi.org/10.1111/eci.14392Karakasis P, Theofilis P, Patoulias D, Schuermans A, Vlachakis PK, Klisic A, Rizzo M, Fragakis N. Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: Systematic review and meta-analysis. Eur J Clin Invest. 2025 Jun;55(6):e14392. https://doi.org/10.1111/eci.14392Ioannou A, Massa P, Patel RK, Razvi Y, Porcari A, Rauf MU, Jiang A, Cabras G, Filisetti S, Bolhuis RE, Bandera F, Venneri L, MartinezNaharro A, Law S, Kotecha T, Virsinskaite R, Knight DS, Emdin M, Petrie A, Lachmann H, Wechelakar A, Petrie M, Hughes A, Freemantle N, Hawkins PN, Whelan C, McMurray JJV, Gillmore JD, Fontana M. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023 Aug 14;44(31):2893-2907. https:// doi.org/10.1093/eurheartj/ehad347. Erratum in: Eur Heart J. 2024 Apr 7;45(14):1251. https://doi.org/10.1093/eurheartj/ehae140Ioannou A, Massa P, Patel RK, Razvi Y, Porcari A, Rauf MU, Jiang A, Cabras G, Filisetti S, Bolhuis RE, Bandera F, Venneri L, MartinezNaharro A, Law S, Kotecha T, Virsinskaite R, Knight DS, Emdin M, Petrie A, Lachmann H, Wechelakar A, Petrie M, Hughes A, Freemantle N, Hawkins PN, Whelan C, McMurray JJV, Gillmore JD, Fontana M. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023 Aug 14;44(31):2893-2907. https:// doi.org/10.1093/eurheartj/ehad347. Erratum in: Eur Heart J. 2024 Apr 7;45(14):1251. https://doi.org/10.1093/eurheartj/ehae140Briasoulis A, Stamatelopoulos K, Petropoulos I, Patras R, Theodorakakou F, Gavriatopoulou M, Ntalianis A, Dimopoulos MA, Kastritis E. Utilization and tolerance of beta-blockers among patients with AL amyloidosis. Amyloid. 2022 Mar;29(1):31-37. https://doi.org/10.1080/13506129.2021.1981281Briasoulis A, Stamatelopoulos K, Petropoulos I, Patras R, Theodorakakou F, Gavriatopoulou M, Ntalianis A, Dimopoulos MA, Kastritis E. Utilization and tolerance of beta-blockers among patients with AL amyloidosis. Amyloid. 2022 Mar;29(1):31-37. https://doi.org/10.1080/13506129.2021.1981281Kwok CS, Choy CH, Pinney J, Townend JN, Whelan C, Fontana M, Gillmore JD, Steeds RP, Moody WE. Effect of beta-blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta-analysis. ESC Heart Fail. 2024 Dec;11(6):3901-3910, https://doi.org/10.1002/ehf2.14975Kwok CS, Choy CH, Pinney J, Townend JN, Whelan C, Fontana M, Gillmore JD, Steeds RP, Moody WE. Effect of beta-blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta-analysis. ESC Heart Fail. 2024 Dec;11(6):3901-3910, https://doi.org/10.1002/ehf2.14975Kang Y, Qu N, Zhang Z, Zhang Q, Chen X, Fu M. Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: A systematic review and meta-analysis. Int J Cardiol. 2024 May 1;402:131813. https://doi.org/10.1016/j.ijcard.2024.131813Kang Y, Qu N, Zhang Z, Zhang Q, Chen X, Fu M. Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: A systematic review and meta-analysis. Int J Cardiol. 2024 May 1;402:131813. https://doi.org/10.1016/j.ijcard.2024.131813Aus dem Siepen F, Hein S, Bauer R, Katus HA, Kristen AV. Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful? Amyloid. 2017 Mar;24(sup1):132-133. https://doi.org/10.1080/13506129.2016.1272453Aus dem Siepen F, Hein S, Bauer R, Katus HA, Kristen AV. Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful? Amyloid. 2017 Mar;24(sup1):132-133. https://doi.org/10.1080/13506129.2016.1272453Aus dem Siepen F, Hein S, Hofmann E, Nagel C, Schwarting SK, Hegenbart U, Schönland SO, Weiler M, Frey N, Kristen AV. Prognostic Value of Standard Heart Failure Medication in Patients with Cardiac Transthyretin Amyloidosis. J Clin Med. 2024 Apr 12;13(8):2257. https://doi.org/10.3390/jcm13082257Aus dem Siepen F, Hein S, Hofmann E, Nagel C, Schwarting SK, Hegenbart U, Schönland SO, Weiler M, Frey N, Kristen AV. Prognostic Value of Standard Heart Failure Medication in Patients with Cardiac Transthyretin Amyloidosis. J Clin Med. 2024 Apr 12;13(8):2257. https://doi.org/10.3390/jcm13082257Bukhari S, Khan SZ, Bashir Z. Atrial Fibrillation, Thromboembolic Risk, and Anticoagulation in Cardiac Amyloidosis: A Review. J Card Fail. 2023 Jan;29(1):76-86. https://doi.org/10.1016/j.cardfail.2022.08.008Bukhari S, Khan SZ, Bashir Z. Atrial Fibrillation, Thromboembolic Risk, and Anticoagulation in Cardiac Amyloidosis: A Review. J Card Fail. 2023 Jan;29(1):76-86. https://doi.org/10.1016/j.cardfail.2022.08.008Vilches S, Fontana M, Gonzalez-Lopez E, Mitrani L, Saturi G, Renju M, Griffin JM, Caponetti A, Gnanasampanthan S, De Los Santos J, Gagliardi C, Rivas A, Dominguez F, Longhi S, Rapezzi C, Maurer MS, Gillmore J, Garcia-Pavia P. Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail. 2022 Aug;24(8):1387-1396. https://doi.org/10.1002/ejhf.2566Vilches S, Fontana M, Gonzalez-Lopez E, Mitrani L, Saturi G, Renju M, Griffin JM, Caponetti A, Gnanasampanthan S, De Los Santos J, Gagliardi C, Rivas A, Dominguez F, Longhi S, Rapezzi C, Maurer MS, Gillmore J, Garcia-Pavia P. Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail. 2022 Aug;24(8):1387-1396. https://doi.org/10.1002/ejhf.2566Nicol M, Siguret V, Vergaro G, Aimo A, Emdin M, Dillinger JG, Baudet M, Cohen-Solal A, Villesuzanne C, Harel S, Royer B, Arnulf B, Logeart D. Thromboembolism and bleeding in systemic amyloidosis: a review. ESC Heart Fail. 2022 Feb;9(1):11-20. https:/ doi.org/10.1002/ehf2.13701Nicol M, Siguret V, Vergaro G, Aimo A, Emdin M, Dillinger JG, Baudet M, Cohen-Solal A, Villesuzanne C, Harel S, Royer B, Arnulf B, Logeart D. Thromboembolism and bleeding in systemic amyloidosis: a review. ESC Heart Fail. 2022 Feb;9(1):11-20. https:/ doi.org/10.1002/ehf2.13701Vilches S, Fontana M, Gonzalez-Lopez E, Mitrani L, Saturi G, Renju M, Griffin JM, Caponetti A, Gnanasampanthan S, De Los Santos J, Gagliardi C, Rivas A, Dominguez F, Longhi S, Rapezzi C, Maurer MS, Gillmore J, Garcia-Pavia P. Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail. 2022 Aug;24(8):1387-1396. https://doi.org/10.1002/ejhf.2566Vilches S, Fontana M, Gonzalez-Lopez E, Mitrani L, Saturi G, Renju M, Griffin JM, Caponetti A, Gnanasampanthan S, De Los Santos J, Gagliardi C, Rivas A, Dominguez F, Longhi S, Rapezzi C, Maurer MS, Gillmore J, Garcia-Pavia P. Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail. 2022 Aug;24(8):1387-1396. https://doi.org/10.1002/ejhf.2566Barbhaiya CR, Kumar S, Baldinger SH, Michaud GF, Stevenson WG, Falk R, John RM. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. Heart Rhythm. 2016 Feb;13(2):383-90. https:// doi.org/10.1016/j.hrthm.2015.09.016Barbhaiya CR, Kumar S, Baldinger SH, Michaud GF, Stevenson WG, Falk R, John RM. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. Heart Rhythm. 2016 Feb;13(2):383-90. https:// doi.org/10.1016/j.hrthm.2015.09.016Donnelly JP, Sperry BW, Gabrovsek A, Ikram A, Tang WHW, Estep J, Hanna M. Digoxin Use in Cardiac Amyloidosis. Am J Cardiol. 2020 Oct 15;133:134-138. https://doi.org/10.1016/j.amjcard.2020,07.034Donnelly JP, Sperry BW, Gabrovsek A, Ikram A, Tang WHW, Estep J, Hanna M. Digoxin Use in Cardiac Amyloidosis. Am J Cardiol. 2020 Oct 15;133:134-138. https://doi.org/10.1016/j.amjcard.2020,07.034Kristen AV, Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H, Sack FU, Voss F, Becker R, Katus HA, Bauer A. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008 Feb;5(2):235-40. https://doi.org/10.1016/j.hrthm.2007.10.016Kristen AV, Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H, Sack FU, Voss F, Becker R, Katus HA, Bauer A. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008 Feb;5(2):235-40. https://doi.org/10.1016/j.hrthm.2007.10.016Клинические рекомендации МЗ РФ «Брадиаритмии и нарушения проводимости» 2025 г. https://cr.minzdrav.gov.ru/viewcr/160_2Clinical guidelines of the Russian Ministry of Health "Bradyarrhythmias and conduction disturbances" 2025. (In Russ.) https://cr.minzdrav.gov.ru/view-cr/160_2]Ando Y, Adams D, Benson MD, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022;29(3):143-155. https://doi.org/10.1080/13506129.2022.2052838Ando Y, Adams D, Benson MD, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022;29(3):143-155. https://doi.org/10.1080/13506129.2022.2052838Masri A, Maurer MS, Claggett BL, et al. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis. J Card Fail. 2024;30(8):973-980. https://doi.org/10.1016/j.cardfail.2023.11.016Masri A, Maurer MS, Claggett BL, et al. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis. J Card Fail. 2024;30(8):973-980. https://doi.org/10.1016/j.cardfail.2023.11.016Hoss S, Habib M, Silver J, et al. Genetic Testing for Diagnosis of Hypertrophic Cardiomyopathy Mimics: Yield and Clinical Significance. Circ Genom Precis Med. 2020;13(2):e002748. https://doi.org/10.1161/CIRCGEN.119.002748Hoss S, Habib M, Silver J, et al. Genetic Testing for Diagnosis of Hypertrophic Cardiomyopathy Mimics: Yield and Clinical Significance. Circ Genom Precis Med. 2020;13(2):e002748. https://doi.org/10.1161/CIRCGEN.119.002748Hagège A, Puscas T, El Hachmi M, et al. The French hypertrophic cardiomyopathy gene register: A systematic large gene screening for hypertrophic cardiomyopathy. Int J Cardiol. 2024;417:132542. https://doi.org/10.1016/j.ijcard.2024.132542Hagège A, Puscas T, El Hachmi M, et al. The French hypertrophic cardiomyopathy gene register: A systematic large gene screening for hypertrophic cardiomyopathy. Int J Cardiol. 2024;417:132542. https://doi.org/10.1016/j.ijcard.2024.132542Cruccu G, Sommer C, Anand P, et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol. 2010;17(8):1010-1018. https://doi.org/10.1111/j.1468-1331.2010,02969.xCruccu G, Sommer C, Anand P, et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol. 2010;17(8):1010-1018. https://doi.org/10.1111/j.1468-1331.2010,02969.xKroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry. 2009;31(3):206-219. https://doi.org/10.1016/j.genhosppsych.2008.12.006Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry. 2009;31(3):206-219. https://doi.org/10.1016/j.genhosppsych.2008.12.006Barge-Caballero G, Barge-Caballero E, López-Pérez M, BilbaoQuesada R, González-Babarro E, Gómez-Otero I, López-López A, Gutiérrez-Feijoo M, Varela-Román A, González-Juanatey C, DíazCastro Ó, Crespo-Leiro MG. Beta-Blocker Exposure and Survival in Patients With Transthyretin Amyloid Cardiomyopathy. Mayo Clin Proc. 2022 Feb;97(2):261-273. Epub 2021 Nov 19. PMID: 34802727. https://doi.org/10.1016/j.mayocp.2021.08.006Barge-Caballero G, Barge-Caballero E, López-Pérez M, BilbaoQuesada R, González-Babarro E, Gómez-Otero I, López-López A, Gutiérrez-Feijoo M, Varela-Román A, González-Juanatey C, DíazCastro Ó, Crespo-Leiro MG. Beta-Blocker Exposure and Survival in Patients With Transthyretin Amyloid Cardiomyopathy. Mayo Clin Proc. 2022 Feb;97(2):261-273. Epub 2021 Nov 19. PMID: 34802727. https://doi.org/10.1016/j.mayocp.2021.08.006Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009 Feb;23(2):215-24. https://doi.org/10.1038/leu.2008.307Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009 Feb;23(2):215-24. https://doi.org/10.1038/leu.2008.307Клинические рекомендации Минздрава России «Другие плазмоклеточные новообразования», 2024 г https://cr.minzdrav.gov.ru/view-cr/883_1Clinical guidelines of the Russian Ministry of Health "Other plasma cell neoplasms", 2024. (In Russ.) https://cr.minzdrav.gov.ru/viewcr/883_1]Lang FM, Teruya S, Cuomo M, Santos AM, Radhakrishnan J, Lentzsch S, Chakraborty R, Bhutani D, Maurer MS. Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain Cardiomyopathy. J Card Fail. 2024 Dec;30(12):1641-1646. https://doi.org/10.1016/j.cardfail.2024.06.009Lang FM, Teruya S, Cuomo M, Santos AM, Radhakrishnan J, Lentzsch S, Chakraborty R, Bhutani D, Maurer MS. Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain Cardiomyopathy. J Card Fail. 2024 Dec;30(12):1641-1646. https://doi.org/10.1016/j.cardfail.2024.06.009Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Rosenberg A, Sborov D, Valent J, Berardi R, Kumar R. Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Jan;21(1):67-81. PMID: 36652935. https://doi.org/10.6004/jnccn.2023.0001Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Rosenberg A, Sborov D, Valent J, Berardi R, Kumar R. Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Jan;21(1):67-81. PMID: 36652935. https://doi.org/10.6004/jnccn.2023.0001Wechalekar AD, Cibeira MT, Gibbs SD, Jaccard A, Kumar S, Merlini G, Palladini G, Sanchorawala V, Schönland S, Venner C, Boccadoro M, Kastritis E. Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid. 2023 Mar;30(1):3-17. https://doi.org/10.1080/13506129.2022.2093635Wechalekar AD, Cibeira MT, Gibbs SD, Jaccard A, Kumar S, Merlini G, Palladini G, Sanchorawala V, Schönland S, Venner C, Boccadoro M, Kastritis E. Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid. 2023 Mar;30(1):3-17. https://doi.org/10.1080/13506129.2022.2093635Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021 Jul 1;385(1):46-58. https://doi.org/10.1056/NEJMoa2028631Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021 Jul 1;385(1):46-58. https://doi.org/10.1056/NEJMoa2028631Sanchorawala V. Summary of the EHA-ISA Working Group Guidelines for High-dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis. Hemasphere. 2022 Jan 27;6(2):e681. https://doi.org/10.1097/HS9.0000000000000681.Sanchorawala V. Summary of the EHA-ISA Working Group Guidelines for High-dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis. Hemasphere. 2022 Jan 27;6(2):e681. https://doi.org/10.1097/HS9.0000000000000681.Liu B, Wang Y, Ning X, Bai M, Wang D, Zhao J, Zhou M, Sun S. A comparative study of cyclophosphamide, thalidomide and dexamethasone (CTD) versus bortezomib and dexamethasone (BDex) in light-chain amyloidosis. Curr Probl Cancer. 2021 Apr;45(2):100669. https://doi.org/10.1016/j.currproblcancer.2020.100669Liu B, Wang Y, Ning X, Bai M, Wang D, Zhao J, Zhou M, Sun S. A comparative study of cyclophosphamide, thalidomide and dexamethasone (CTD) versus bortezomib and dexamethasone (BDex) in light-chain amyloidosis. Curr Probl Cancer. 2021 Apr;45(2):100669. https://doi.org/10.1016/j.currproblcancer.2020.100669Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan and dexamethasone for light chain amyloidosis. J Clin Oncol. 2020; 38(28): 3252-3260. https://doi.org/10.1200/jco.20.01285Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan and dexamethasone for light chain amyloidosis. J Clin Oncol. 2020; 38(28): 3252-3260. https://doi.org/10.1200/jco.20.01285Schwotzer R, Flammer AJ, Gerull S, Pabst T, Arosio P, Averaimo M, Bacher VU, Bode P, Cavalli A, Concoluci A, Dirnhofer S, Djerbi N, Dobner SW, Fehr T, Garofalo M, Gaspert A, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pazhenkottil A, Pfister O, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stirnimann G, Suter T, Théaudin M, Treglia G, Tzankov A, Vetter F, Zweier M, Gerber B. Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis. Swiss Med Wkly. 2020 Dec 5;150:w20364. https://doi.org/10.4414/smw.2020.20364Schwotzer R, Flammer AJ, Gerull S, Pabst T, Arosio P, Averaimo M, Bacher VU, Bode P, Cavalli A, Concoluci A, Dirnhofer S, Djerbi N, Dobner SW, Fehr T, Garofalo M, Gaspert A, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pazhenkottil A, Pfister O, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stirnimann G, Suter T, Théaudin M, Treglia G, Tzankov A, Vetter F, Zweier M, Gerber B. Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis. Swiss Med Wkly. 2020 Dec 5;150:w20364. https://doi.org/10.4414/smw.2020.20364Palladini G, Milani P, Foli A. et al. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients. Leukemia. 2014;28:2311-2316. https://doi.org/10.1038/leu.2014.227Palladini G, Milani P, Foli A. et al. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients. Leukemia. 2014;28:2311-2316. https://doi.org/10.1038/leu.2014.227Р Рехтина И.Г., Менделеева Л.П. Современные критерии диагностики AL-амилоидоза. Врач. 2022;33(7):82-86. https://doi.org/10.29296/25877305-2022-07-17Rekhtina I., Mendeleeva L. Current diagnostic criteria for AL amyloidosis. Vrach. 2022;33(7):82-86. (In Russ.) https://doi.org/10.29296/25877305-2022-07-17]Kumar SK, Hayman SR, Buadi FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for lightchain amyloidosis: long term results from a phase 2 trial. Blood. 2012;119:4860-4867. https://doi.org/10.1182/blood-2012-01-407791Kumar SK, Hayman SR, Buadi FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for lightchain amyloidosis: long term results from a phase 2 trial. Blood. 2012;119:4860-4867. https://doi.org/10.1182/blood-2012-01-407791Palladini, G., Russo, P., Foli, A. et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol . 2012 Jan;91(1):89-92. https://doi.org/10.1007/s00277-011-1244-xPalladini, G., Russo, P., Foli, A. et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol . 2012 Jan;91(1):89-92. https://doi.org/10.1007/s00277-011-1244-xKastritis E, Minnema C, Dimopoulos M, et al. Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network. (ASH Annual Meeting Abstracts). 2022;2730.Kastritis E, Minnema C, Dimopoulos M, et al. Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network. (ASH Annual Meeting Abstracts). 2022;2730.Manwani R, Cohen O, Sharpley F, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134(25):2271-2280. https://doi.org/10.1182/blood.2019000834Manwani R, Cohen O, Sharpley F, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134(25):2271-2280. https://doi.org/10.1182/blood.2019000834Fotiou D, Dimopoulos MA, Kastritis E. Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management. Hemasphere. 2020; 4(4):e454. https://doi.org/10.1097/hs9.0000000000000454Fotiou D, Dimopoulos MA, Kastritis E. Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management. Hemasphere. 2020; 4(4):e454. https://doi.org/10.1097/hs9.0000000000000454Gertz MA, Lacy MQ, Dispenzieri A, et al. Trends in day 100 and 2-year survival after auto- SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant. 2011; 46:970-975. https://doi.org/10.1038/bmt.2010.234Gertz MA, Lacy MQ, Dispenzieri A, et al. Trends in day 100 and 2-year survival after auto- SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant. 2011; 46:970-975. https://doi.org/10.1038/bmt.2010.234Sidiqi MH, Aljama MA, Buadi FK, et al. Stem cell transplantation for light chain amyloidosis: decreased early mortality over time. J Clin Oncol. 2018;36(13):1323-9. https://doi.org/10.1200/jco.2017.76.9554Sidiqi MH, Aljama MA, Buadi FK, et al. Stem cell transplantation for light chain amyloidosis: decreased early mortality over time. J Clin Oncol. 2018;36(13):1323-9. https://doi.org/10.1200/jco.2017.76.9554Sidana S, Sidiqi MH, Dispenzieri A, et al. Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. Am J Hematol. 2019;94(9):1020-6. https://doi.org/10.1002/ajh.25566Sidana S, Sidiqi MH, Dispenzieri A, et al. Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. Am J Hematol. 2019;94(9):1020-6. https://doi.org/10.1002/ajh.25566Roussel M, Merlini G, Chevret S, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic lightchain amyloidosis. Blood . 2020 Apr 30;135(18):1531-1540. https://doi.org/10.1182/blood.2019004369Roussel M, Merlini G, Chevret S, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic lightchain amyloidosis. Blood . 2020 Apr 30;135(18):1531-1540. https://doi.org/10.1182/blood.2019004369Milani P, Sharpley F, Schönland SO, et al. Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. Amyloid. 2020;27(4):231-236. https://doi.org/10.1080/13506129.2020.1767566Milani P, Sharpley F, Schönland SO, et al. Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. Amyloid. 2020;27(4):231-236. https://doi.org/10.1080/13506129.2020.1767566Solomon A, Weiss DT, Wall JS. Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother Radiopharm. 2003 Dec;18(6):853-60. https://doi.org/10.1089/108497803322702824Solomon A, Weiss DT, Wall JS. Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother Radiopharm. 2003 Dec;18(6):853-60. https://doi.org/10.1089/108497803322702824Popkova T, Hajek R, Jelinek T. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits. Br J Haematol. 2020 Apr;189(2):228-238. https://doi.org/10.1111/bjh.16436Popkova T, Hajek R, Jelinek T. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits. Br J Haematol. 2020 Apr;189(2):228-238. https://doi.org/10.1111/bjh.16436

The authors declare that there are no conflicts of interest present.